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Abstract 
 
Background: Cerebellar neural stem cells (NSCs) maintenance is of great interest since NSCs can 
be used to treat impaired cells and tissues or improve regenerative power of degenerating cells in 
neurodegenerative diseases or spinal cord injuries. Under maintenance conditions, NSCs express 
a number of Hedgehog-Gli (Hh-Gli) linked and stemness genes (e.g. Nanog, Oct4, Sox2) whose 
mechanisms of regulation have been under investigation. However, the interplay between 
transcription factors and microRNAs in NSCs is still being charted.  
Aim: Identification of new molecular players involved in NSCs’ maintenance with particular interest 
in the major regulatory pathway Hedgehog-Gli. 
Materials and Methods: Cells used for the study were NSCs isolated from postnatal day 4 (P4) wild 
type (C57BL/6) mice cultured both as neurospheres in selective medium and as differentiated NSCs 
when cultured in medium with serum. NSCs and their differentiated counterparts were analysed by 
high-throughput technologies. Bioinformatics analysis was used for the identification of the Foxm1-
regulated miRNAs; knock-down experiments and clonogenic assays were used for functional 
studies. Chromatin immunoprecipitation experiments (ChIP) were used to investigate the binding 
between Foxm1 and its targets and between Foxm1 and its regulators. 
Results: NSCs and their differentiated counterparts were analysed using next-generation mRNA- 
and miRNA-sequencing. The transcriptional analysis allowed the identification of Foxm1 as one of 
the highest transcripts in NSCs and the miRNA-sequencing provided a number of highly expressed 
miRNAs. The use of bioinformatics analysis resulted in the Foxm1-regulated miRNAs, miR-15 ~ 16 
cluster, miR-17 ~ 92 cluster, miR- 130b and miR-301a. Functional experiments, such as knock-down 
experiments and clonogenic assays enabled the identification of Foxm1 as a downstream mediator 
of the Hh-Gli signalling and with the ability to regulate the above mention miRNAs.  
Conclusion: The study presented reveals a new Foxm1-microRNAs network with a major role in 
the maintenance of NSCs. These results add a previously unidentified important molecular aspect 
that could be used in future neurodegenerative disease studies, thus enriching the field of 
translational medicine.   
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Introduction  
Neural stem cells 
Stem cells have been a major focus of research because of their unique capacities of self-renewal 
and differentiation capacity. These capacities are defined by the expression of transcription factors 
and epigenetic modulations (Montalbán-Loro, R. et al. 2015). 
They reside in specific environment or niches of the adult mammalian brain, the subgranular zone 
of the dentate gyrus of the hippocampus (SGZ), the subventricular zone (SVZ) lining the lateral 
ventricles, and the white matter of the cerebellum (Gage, F.H. 2000; Lee, A.  et al., 2005), in which 
NSCs support neurogenesis and gliogenesis during adult life.  A small number of NSCs may still be 
in other areas of the brain (Fig. 1).  
In SGZ there are two types of NSCs, particularly type 1 that are quiescent characterized by the 
expression of specific molecular markers such as glial fibrillary acidic protein (GFAP), Nestin and 
Sox2. Type-1 NSCs (true stem cells) are the neurogenic entities that generate type-2 cells that 
proliferate actively and express Nestin, Sox2 but not GFAP. 
In the SVZ area three types of NSCs can be distinguished (Fig. 2): A, B, C. Type-A is composed of 
migratory neuroblasts, type-B and -C correspond to type 1 and 2 in SGZ (Yao J. et al., 2012). The 
cell lineage differentiation goes from type-B, through type-C to type-A cells (Doetsch F. et al., 1999). 
 
Figure 1. Postnatal mammalian neuronal stem cell "niches". 
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Figure 2. Cytoarchitecture of the subventricular zone of the healthy adult brain (Martino G. and 
Pluchino S. 2006). 
 
Neural cerebellar Stem Cells (NSCs) have the ability to self-renewal and to give rise to neurons, 
astrocytes and oligodendrocytes (Fig. 3) (Davis, A. A. and Temple, S. 1994; Gage, F.H. 2000). They 
express stemness markers such as Sox2, Nestin, Nanog and Prom1 (Palm, T. et al., 2013; Po, A. 
et al., 2010). 
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Figure 3. Self-renewal of Neural cerebellar Stem Cells and differentiation lineage (Wakabayashi, T. 
et al., 2014). 
 
NSCs are in physical contact with the basal lamina, which regulates cytokines and growth factors 
derived from local cells (Campos, L. S.  et al. 2006). 
Moreover, the proliferation and differentiation are finely regulated by both intrinsic and extrinsic 
factors (Imayoshi, I. et al., 2010; Pierfelice, T. et al., 2011) consisting of morphogens, growth factors, 
tissue micro-environment (germinal niche), transcriptional factors and epigenetic mechanisms. 
Among the main determinants of differentiation, Notch is responsible for neuronal differentiation 
(Imayoshi, I.  et al., 2010; Pierfelice, T. et al., 2011), fibroblast growth factor (FGF), WNT that 
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promotes differentiation in the subventricular zone (Lie, D.C. et al., 2002) and Sonic Hedgehog 
directs NSCs to the glial lineage (Ahn, S., and Joyner, A.L. 2005; Balordi, F., and Fishell, G., 2007; 
Han, Y.-G. et al. 2008). 
NSCs are characterized by a low degree of epigenetic silencing, resulting in the activation of a 
multitude of genes that maintain self-renewal (Yao J. et al.,2012). 
Up-regulated pathways consistent with NSCs self-renewal have been identified, such as G1-S cell 
cycle regulation, nucleic acid synthesis, DNA replication, packaging, and repair genes (Gage, F.H. 
2000). 
Advancing the understanding of the signalling molecules that are responsible for the transition of 
NSCs from proliferation to differentiation will further the potential use of NSCs as therapeutic agents 
(Gage, F.H. 2000; Harris, L. et al., 2016). 
There are cues that NSCs can reach the target organ and differentiate into the appropriate cell 
lineage but the molecular mechanisms that sustain functional integration and repair capabilities are 
not clear (Martino G., Pluchino S., 2006). 
The main goal is to use NSCs to treat impaired cells and tissues or improve regenerative power of 
degenerating cells in neurodegenerative diseases (for example Parkinson’s disease, Huntington’s 
disease, multiple sclerosis) or spinal cord injuries. 
 
Hedgehog pathway in NSCs 
A key signal sustaining NSCs is Hedgehog (Hh) signalling (Po, A. et al., 2010).  Hh pathway has a 
central role in development and tumorigenesis in a wide variety of tissues, both processes being 
supported by stem cells (Ahn, S., and Joyner, A.L., 2005; Lai, K. et al., 2003; Palma, V. and i Altaba, 
A.R. 2004; Palma, V. et al., 2005). 
The pivotal role of this signal pathway has already been described in embryonic stem cells and NSCs 
of SVZ, hippocampal regions (Ahn, S., and Joyner, A.L., 2005; Lai, K. et al., 2003; Palma, V. et al., 
2005; Palma, V. and i Altaba, A.R. 2004) and cerebellum (Po, A. et al., 2010). 
The canonical Hh pathway requires the presence of a transmembrane receptor, Smoothened (Smo), 
which can be inhibited by the Patched 1 (Ptc) receptor. Hh ligands (Desert Hedgehog (DHH), Indian 
Hedgehog (IHH), and Sonic Hedgehog (SHH) bind Ptc which is internalized, degraded, and thus not 
able to inhibit the activator receptor Smo.  Smo, then, interacts and inhibits the Suppressor of fused 
(SUFU), this results in the activation and nuclear translocation of the only known transcriptional 
mediators of the Hh response, zinc-finger proteins of the glioma-associated oncogene (Gli) family. 
These are bifunctional transcription factors that can both activate or inhibit transcription. In detail, 
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Gli1 and Gli2 (GliA) are activated and transported in the nucleus where they activate the transcription 
of Gli1 itself, Gli2 and Ptc, thus amplifying the Hh signaling pathway. Gli3 (GliR) is a suppressor of 
the Hh pathway and is degraded after inhibition of Sufu by Smo (Fig. 4) (Ng, J.M., and Curran, T., 
2011). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Hedgehog signaling pathway. 
 
In NSCs Nanog and Hh/Gli are co-expressed and it has been demonstrated that both are essential 
in driving self-renewal. Nanog is a transcriptionl factor essential for maintaining the pluripotency of 
the inner cell mass during embryonic development and its expression is down regulated in 
differentiated cells. Nanog is a downstream factor of the Hh signal transduction, in fact Gli1 and Gli2 
bind to specific consensus cis-regulatory responsive elements on Nanog promoter enhancing its 
transcription. This way, Gli1 and Gli2 mediate the Hh-dependent control of Nanog and downstream 
stemness genes, which promote self-renewal of NSCs (Po, A. et al., 2010). 
 
 
  
9 
 
Next Generation Sequencing 
In 1977 F. Sanger and colleagues proposed a new innovative method for sequence DNA by chain 
termination and fragmentation techniques (first generation), that was used for the next 30 years, 
introducing the possibility to study genomes and for fast and low-cost DNA sequencing.  
The Human Genome Project (HGP) (Consortium, I.H.G.S. 2004; Lander, E.S. et al., 2001), was an 
international, publicly funded consortium of scientists at universities and research institutes with the 
aim to provide a virtually complete sequence of human DNA, the genome.  
The Sanger methods allowed the realization of the first human genome sequence in 2004. HGP was 
still very expensive and needed plenty of resources, so, in the same year the National Human 
Genome Research Institute (NHGRI) started a program to reduce the cost of the sequencing to 
US$1000 in ten years. This has led to the development of next-generation sequencing (NGS) 
technologies. These new technologies offered improvements respect to Sanger methods. First, in 
the preparation of libraries in a cell free system to fragment the DNA; second, they could generate 
gigabases of genomic data in a single run because the sequencing reactions are produced in 
parallel; and lastly, they didn’t require the electrophoresis step (Van Dijk, E.L. et al., 2014).  In this 
way, they largely reduced the cost and the complexity of the experiments.   
NGS systems are based on shotgun sequencing approach which consists of random fragmentation 
from an entire genome, transcriptome, or smaller targeted regions and sequencing of DNA in a single 
run (Morozova, O. et al. 2009). 
There are different commercial platforms, the widely utilized ones are Roche/454, Illumina, Applied 
Biosystems SOLiD, Oxford Nanopore, Ion Torrent, Pacific Biosciences and Helicos. They differ from 
each other on the type of chemistry used, in fact they can be based on either “sequencing by 
synthesis” or “sequencing by ligation” detection methods (Metzker, M.L. 2010). 
The advantage of New-Generation Sequencing Methods can be applied to different areas of 
research and for different applications. These include a complete genome annotation, for example 
the knowledge of all regulatory sequences, splice variants and exon-intron structures (Morozova, O. 
et al., 2009). Omics technologies provided us data that allowed us to better understand the 
genotype–phenotype interaction. NGS has a wide application in the identification and quantifying of 
transcripts in cells, tissue and organisms (RNA-seq) (Morozova, O. et al., 2009; Voelkerding, K. V. 
et al., 2009).   
In genomics they allow us to study whole genomes from microbes to humans and its products, and 
the communication between genes and environment. In the medical field NGS advances have 
improved the understanding of the relationship between genetic modification and phenotype, 
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moreover the re-sequencing of target genomic regions is useful to identify polymorphisms in genes 
to study rare variants in genetic diseases (Koboldt, D.C. et al., 2013; Voelkerding, K. V. et al., 2009).   
 
RNA-Sequencing 
The RNA sequencing, through NGS, allows for the quantification and characterization of transcripts, 
producing an adequate representation of transcriptome in both prokaryotes and eukaryotes. These 
technologies avoid several problems connected to the hybridization-based microarrays, previously 
used to gene expression, such as cross-hybridization artefacts, limited range of detection and a priori 
knowledge of gene sequences.  
There are several applications of RNA-seq in transcriptomics that have an important impact on the 
study of diseases. For example, it is used for the characterization of splicing variants that could help 
us to understanding the contribution of alternative splicing in the development of human diseases. 
In the field of cancer research, it also can be used to find gene fusion events, such as a translocation 
or another genomic arrangements that produce aberrant RNAs, identifying potential targets for 
therapeutic approach (Ozsolak, F., and Milos, P. M., 2011). 
It is largely used to map transcription start sites, to identify nucleotide variations and mutations and 
noncoding RNAs (ncRNAs) expression profiling in many species. RNA-seq is effective not only in 
the discovery of novel microRNAs and siNAs, but also in the detection of variants of microRNAs and 
editing events (Morozova, O. et al. 2009). 
RNA-seq workflow (Fig. 5) starts with the conversion of total RNA in a library of cDNA containing 
sequencing adaptors. Then, each molecule is sequenced to obtain short sequences (reads) from 
one end (single-end sequencing) or both ends (pair-end sequencing). The size of the resulting reads 
obtained are very short, between 35 and 500 bp (Wang, Z. et al., 2009), so it is necessary to 
reassembly the full-length RNAs, except in the case of small classes of RNA (miRNAs, piRNAs 
snoRNAs and siRNAs). Following sequencing, there are three different strategies to perform the 
assembly of the transcriptome: a reference-based strategy, a de novo strategy or a combined 
strategy that merges the two. The “reference-based” is easier to perform, it aligns the reads to a 
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reference genome and the advantage is that can assemble transcripts of low abundance (Martin, 
J.A. and Wang, Z., 2011). 
 
 
 
 
Figure 5. Example of a typical RNA-sequencing experiment (Martin, J.A. and Wang, Z., 2011). 
12 
 
MicroRNAs  
The discovery of microRNAs twelve years ago (Ambros, V., 2004) brought to the forefront of 
epigenetic research the post-transcriptional gene regulation.  
MicroRNAs are known to be involved in the maintenance of stem cell self-renewal and promotion of 
differentiation (Blakaj A, Lin H. 2008; Tay, Y. et al. 2008).  
MicroRNAs are a class of small (~22 nt) non-coding RNAs that bind through a 5´ “seed region” to 
the 3´untranslated region (3´ UTR) of target mRNAs driving them to translation repression and/or 
mRNA degradation (Fig. 6) (Bartel, D.P. 2009).  
It has been estimated that since microRNAs only need as few as 7 nucleotides of complementarity 
to bind to their target, computational and experimental approaches indicate that more than 60% of 
human protein coding genes are predicted to contain microRNA-binding sites. This fact highlights 
the necessity for microRNA profiling in order to acquire a more complete understanding of their 
identity and role in different biological contests. The small size of mature microRNAs renders them 
suitable for characterization using RNA-seq technologies by implementing the appropriate 
modifications in sequencing and bioinformatics analysis. 
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Figure 6. Biogenesis and function of microRNAs in mammals. 
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Scope of the study 
 
Since the discovery of NSCs, researchers have focused on maintenance mechanisms of these cells. 
The main goal is to use them to treat impaired tissues or to improve regenerative power of 
degenerating cells in neurodegenerative diseases or spinal cord injuries. Under maintenance 
conditions, NSCs express several stemness genes (e.g. Nanog, Oct4, Sox2) whose mechanisms of 
regulation have been investigated (Garg, N. et al., 2013; Po, A. et., 2010; Kim, J. B., 2009; Zhang 
S, Cui W., 2014). However, the interplay between other transcription factors and NSCs maintenance 
is still being charted. 
Therefore, the aim of the study was to understand stemness molecular mechanisms, investigating 
the role of transcription factors and microRNAs, in NSCs compared to their differentiated 
counterparts. With this aim next-generation RNA sequencing was used that allowed the identification 
of transcripts and microRNAs characterizing NSCs. The highest expressed transcript in NSCs 
implicated in the Hh signaling was Forkhead Box m1 (Foxm1), part of the FOX superfamily of 
transcriptional regulators that play a pivotal role in cell cycle progression. Therefore, the study 
focused on identifying a Foxm1-microRNA network involved in maintaining NSCs. 
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Results 
High-throughput transcriptome profiling of cerebellar NSCs 
Cerebellar NSCs from postnatal day 4 (P4) mice were grown in stem-cell-selective medium, as 
described elsewhere (Po, A. et al., 2010). As expected, under these conditions, the cells displayed 
high-level expression of stemness genes (Nanog, Nestin) and of Gli1 (Fig. 7A). Transfer of these 
NSCs to differentiation medium (Po, A. et al., 2010) was followed by significant increases in the 
expression of genes encoding astrocytic, neuronal, Purkinje, and oligodendrocytic cell markers (Fig. 
7B). 
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Figure 7. Characterization of P4 murine cerebellar NSC cultures before and after differentiation. 
A Heatmap: Levels of mRNA for markers of stemness (Nanog, Nestin), Hh-Gli signaling (Gli1), and 
neuronal differentiation (Neurod1, Math1) in NSCs grown in stem-cell-selective medium. Transcript 
levels are represented on a green-red color scale based on ΔCt values. Immunofluorescence 
images: Representative results of NSC staining for markers of stemness and Hh-Gli signalling 
(green); nuclei are counterstained with Hoechst (blue). 
B Left: Levels of mRNA for genes encoding neuronal differentiation markers in NSCs grown for 48 
h in differentiation medium (Diff-NSCs), as measured by RT-qPCR single assays. P values vs. pre-
differentiation NSC controls: **P<0.01: 0.0019 (S100 P), 0.0083 (Pvalb); *P<0.05: 0.0298 (Tubb3), 
0.0316 (Cspg4) (unpaired T-test). Right: Representative results of immunofluorescence staining of 
Diff-NSCs for neuronal differentiation markers (green); nuclei are counterstained with Hoechst 
(blue). Scale bar: 5 µm for all panels. 
 
Paired-end polyA+ RNA-sequencing was used to profile the transcriptomes of NSCs grown in stem 
cell and differentiation media (NSCs and Diff-NSCs, respectively; three replicates of each). A total 
of 988 genes were differentially transcribed by the cells under these two conditions. NSCs and Diff-
NSCs were clearly segregated, as observed in the hierarchical clustering of the 988 differentially 
expressed transcripts (DETs) (Fig. 8 and Supplementary Table 5). 
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Figure 8. Clustering of differentially expressed transcripts (DETs) in NSCs and Diff-NSCs. 
Hierarchical clustering of the 988 transcripts differentially expressed (adj. P < 0.05) (Bray-Curtis 
method with average linkage). 
 
Functional analysis of the DETs using the DAVID platform (Database for Annotation, Visualization 
and Integrated Discovery) revealed significant enrichment (Bonferroni-corrected P<0.05) for the four 
Gene Ontology categories reported in Table 1 and detailed in Figure 9. The most interesting clue 
that emerged from this analysis was the over-representation of genes involved in p53 signalling. This 
pathway is a well-known negative regulator of NSCs self-renewal (Garg, N. et al., 2013; Solozobova, 
V. & Blattner, C., 2011), whose activity is modulated by signalling through the Hh-Gli-Nanog axis 
(Lin, T. et al., 2005; Po, A. et al., 2010). 
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Figure 9. Functional analysis of DETs in NSCs and Diff-NSCs. 
Functional analysis with DAVID (see Table 1). Clusters are shown with heat maps indicating 
transcript abundance (based on normalized FPKM values) for genes belonging to each Gene 
Ontology (GO) category. 
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Hedgehog–Gli pathway components enriched in NSCs  
In order to identify other molecular players with potential roles in Hh-Gli-driven self-renewal of 
cerebellar NSCs, a compiled list of 53 genes known to be regulated by Hh-Gli signalling in settings 
(physiologic or pathologic) other than NSCs (Supplementary Table 1) was used. Nine of these 
genes were differentially transcribed in NSCs before and after differentiation (Supplementary Table 
2, Figure 10). Six of the nine genes encode cyclins (Ccnb2, Ccnb1, Ccna2, Ccnd2, Ccne1, Ccnd1) 
known to be involved in the regulation of cell cycle and cell division in NSCs.  The seventh, Sema6a, 
is involved in nervous system development, in particular, in axon guidance (Rivron, N. C. et al., 
2012), and the eighth gene, Insm1, has been reported to be involved in mouse cerebellar 
development (De Smaele, E. et al., 2008). 
Analysis of this list revealed that Foxm1 was the Hh-Gli-regulated transcription factor most markedly 
expressed in NSCs prior to differentiation.  Foxm1 is a transcriptional activator (Wierstra, I., 2013) 
whose role as a downstream mediator of Hh-Gli signalling has been documented exclusively in 
human cancer cells (Teh, M.T. et al., 2002; Katoh, Y. and Katoh, M. 2006; Shi, C. et al., 2016). The 
relation between Foxm1 and Hh-Gli signalling was evident in our NSC model. Consistent with their 
high-level expression of Gli1 (Fig. 7A), the NSCs displayed strikingly higher levels of Foxm1—at 
both the transcriptional (Fig. 11A) and protein levels (Fig. 10B)—prior to their differentiation. Review 
of our mRNA-seq data confirmed this NSC-associated upregulation for two of the four known protein-
coding Foxm1 transcript isoforms (ENSMUST00000073316 [Foxm1-201] and 
ENSMUST00000112148 [Foxm1-202]). As shown in Figure 11B, this finding was validated by PCR 
performed with isoform-specific primers and by immunoblot analysis, which revealed clear 
predominance in the NSCs of the 757-amino-acid Foxm1-201 protein isoform.   
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Figure 10. The Hh-signalling mediator Foxm1 is differentially expressed in NSCs and Diff-NSCs. 
A Heatmap and dendrogram of the nine DETs whose genes are regulated by Hh signalling. 
B Immunofluorescence staining of endogenous Foxm1 (green) in NSCs and in Diff-NSCs. Nuclei 
were counterstained with Hoechst (blue). Scale bar: 5 m. 
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Figure 11. Upregulated expression of Foxm1 in P4 cerebellar NSCs and its effect on self-renewal.  
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A RT-qPCR data showing differential expression in pre- and post-differentiation NSCs of mRNA for 
Foxm1 (*****P<0.0001: 0.0000089) and the neuronal differentiation gene Tubb3 (*P<0.05: 0.029) 
(Mann–Whitney U test).  
B Left: PCR assay of Foxm1 expression using isoform-specific primers. Agarose (2%) gel separation 
of the amplified product yielded two bands corresponding to Foxm1 isoforms 201 (400 bp) and 202 
(300 bp). Right: Immunoblots showing endogenous levels of Foxm1, Tubb3, and Actin (loading 
control) in three NSC cultures before and after induced differentiation.  
C Left: Immunoblots showing endogenous levels of Foxm1 and Hsp70 (loading control) in NSCs 
transfected with siRNA against Foxm1 or non-targeting siRNA controls (siCtrl). Densitometric values 
appear below blots.  
Right: Representative bright-field images of neurospheres formed by NSCs transfected with siCtrl 
and siFoxm1. Scale bar: 100μm. Graphs show percentages of seeded cells that formed 
neurospheres (*P<0.05: 0.036) (Two-tailed paired t-test).  
Bars in panels A and C represent the mean (SD) of three independent experiments.  
 
Foxm1 mediates Hh–Gli-driven self-renewal of the NSCs 
To explore the functional relevance of this upregulation, NSCs  were transfected with siRNA directed 
against Foxm1 (siFoxm1) and evaluated  for their self-renewal capacity, as reflected by their ability 
to form neurospheres. As shown in Figure 11C, Foxm1 knock-down was associated with 
significantly impaired neurosphere formation.  
Comparison of the human FOXM1 and murine Foxm1 promoter regions revealed a high percentage 
of identical base pairs (36%-45%), which indicated substantial similarity. Consistent with recent 
findings on its human ortholog (Shi, C. et al., 2016; Wang, D. et al., 2017), the murine Foxm1 
promoter was found to harbour eight putative Gli-binding sites (s1–s8) (Figure 12A and 
Supplementary Information-Section 1). Quantitative PCR-ChIP assays were performed in order 
to determine whether both transcriptional activators of the Hh-Gli pathway could occupy the Foxm1 
promoter in these putative binding sites.  Experiments were performed in NSCs both before and after 
differentiation to quantitatively assess Gli recruitment and histone H3 acetylation (AcH3, a marker of 
transcriptional activation). Transcriptional activation was reported in all putative Gli binding sites (s1-
5) and (s6-8) as evidenced by the higher percentage of promoter occupancy in NSCs when 
compared to Diff-NSCs. In particular, Gli2 reported a significantly higher percentage of occupancy 
in the Gli (s1-5) binding sites of the Foxm1 promoter in NSCs in respect to Diff-NSCs (Fig. 12B). 
Similarly, Gli1 promoter occupancy in the Gli (s6-8) binding sites of the Foxm1 promoter was 
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significantly higher in NSCs when compared to Diff-NSCs (Fig. 12C). These data concluded that Gli-
binding sites were bound by both transcriptional activators of the Hh-Gli pathway in NSCs.  
Luciferase reporter assays showed significant activation of Foxm1 by Gli2 binding and to a 
somewhat lesser extent by the binding of Gli1 (Fig. 12D). Collectively, these findings strongly support 
the importance of Foxm1 as a major mediator of Hh–Gli-driven self-renewal of the NSCs phenotype 
in the post-natal murine cerebellum. 
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Figure 12. Foxm1 promoter occupancy by Gli1 and Gli2. 
Fig 3.	
Foxm1 
+1 
-2649 -2574 -2523 
s2 s3 
Gli Binding Sites 
Ch6, GRCm38.p2 
 
s4 
-2668 
s5 
-2692 
-2498 
s6 
s1 
s7 s8 
-3066 -3398 -3151 
-3954 
TSS 
A
B
C
PC
DN
A
GL
I1
GL
I2
0
1
2
3
4
** 
F
-L
u
c
if
e
ra
s
e
:R
-L
u
c
if
e
ra
s
e
 
PCDNA li1 li2 
* 
D
Gl
i1
Gl
i2
Ac
H3
0.0000
0.0025
0.0050
0.15
0.20
0.25
0.30
P
ro
m
o
te
r 
o
c
c
u
p
a
n
c
y
 (
%
)
NSC
Diff-NSC
Gli s1-5li s1-5 
* 
* 
P
ro
m
o
te
r 
o
c
c
u
p
a
n
c
y
 (
%
) 
 
NS 
Gl
i1
Gl
i2
Ac
H3
0.00
0.02
0.04
0.5
1.0
1.5
2.0
2.5
Gli s6-8
P
ro
m
o
te
r 
o
c
c
u
p
a
n
c
y
 (
%
)
NSC
Diff-NSC
Gli s6-8 
** 
* 
P
ro
m
o
te
r 
o
c
c
u
p
a
n
c
y
 (
%
) 
 
NS 
25 
 
A Schematic of the Foxm1 promoter showing locations of the 8 putative Gli-responsive elements 
(s1–s8).  
B-C qPCR-ChIP assay of endogenous Gli1 and Gli2 occupancy of the Foxm1 promoter region in 
NSCs and Diff-NSCs. Immunoprecipitation with anti-acetyl-H3 antibodies was used to detect Foxm1 
transcriptional activation. Eluted DNA was qPCR-amplified using primers for putative Gli binding 
sites [s1–s5 (B) and s6–s8 (C)]. Results are expressed as fold induction values relative to ChIP input 
controls. Bars represent means (SD) of three independent experiments. P values vs. Diff-NSCs 
(Mann-Whitney U test): (B) *P<0.05: 0.04797 (s1-5, Gli2), 0.03271 (s1-5, AcH3); NS (not significant): 
0.2514 (s1-5, Gli1). (C) *P<0.05: 0.0490 (s6-8, AcH3); **P<0.01: 0.001374 (s6-8, Gli1); NS: 
0.296763205 (s6-8, Gli2). 
D Luciferase activity induced in the Foxm1 promoter region in 293T cells by Gli1, Gli2, and PCDNA 
(negative control). Results are normalized to pRL-CMV-Renilla luciferase (R-Luciferase). Bars 
represent means (SD) of at least three independent experiments, each performed in triplicate.  P 
values vs. control cells (One-way ANOVA test):  *P<0.05: 0.02 (Gli1); **P<0.01: 0.005 (Gli2). 
 
Foxm1 modulates stemness through the activation of specific microRNAs in NSCs 
As previously noted, the Hh-Gli-regulated stemness marker, Nanog, modulates the proliferation and 
self-renewal of murine cerebellar NSCs via miRNA-mediated suppression of genes promoting cell-
cycle arrest and differentiation (Garg, N. et al., 2013; Po, A. et al., 2010). This observation lead to 
the question whether miRNAs might also play a role in Foxm1’s effects on NSC self-renewal. As 
shown in Figure 13A, miRNA-sequencing studies identified 80 microRNAs that were differentially 
expressed in NSCs and Diff-NSCs.  
To identify miRNAs likely to be direct targets of Foxm1, the promoter regions of the 40 miRNAs that 
were upregulated in NSCs (Supplementary Table 3) were examined and putative Foxm1 binding 
sites were found in 20. To increase the chances of identifying targets with biological relevance to 
NSC self-renewal, subsequent analyses were restricted to the 15 miRNAs on this list with the most 
statistically significant upregulated expression in the NSCs (Table 2, Fig. 14). (See Supplementary 
Information-Section 2 for the promoter regions of the miRNAs). 
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Figure 13. Foxm1 controls the transcription in P4 murine cerebellar NSCs of multiple miRNAs and 
miRNA clusters that affect NSC neurosphere formation. 
A Heat map and dendrogram depiction of the 80 miRNAs displaying significant differential 
expression in NSCs before and after induction of differentiation. 
B-C qPCR-ChIP assays of NSCs and Diff-NSCs using anti-Foxm1 antibody and anti-acetyl-H3 
antibody. Eluted DNA was PCR-amplified with primers annealing to promoter regions of the 
microRNA genes of interest. Findings for miRNA candidates belonging to a cluster are based on 
assays of one representative cluster member. Results are expressed as fold induction versus input 
controls.  Bars represent the mean (SD) of three independent experiments. P values NSCs vs. Diff-
NSCs (Mann–Whitney U test):  
Statistically significant (B) Foxm1: **P<0.01: 0.002204 (miR-17~92); ***P<0.001: 0.000 (miR-
15b~16-2), 0.0003471 (miR-130b), 0.00004 (miR-15a~16-1), 0.0003906 (miR-301a).  
AcH3: *P<0.05: 0.049416827 (miR-15b~16-2); **P<0.01: 0.008868 (miR-130b); ***P<0.001: 
0.0008656 (miR-17~92), 0.00000069 (miR-15a~16-1), 0.00000920 (miR-301a). Not Significant  
(C) Foxm1: *P<0.05: 0.01467 (miR-335), 0.01021 (miR-106b~25); NS: not significant: 0.07214 (miR-
130a). AcH3: *P<0.05: 0.02903 (miR-130a); NS: 0.5259 (miR-335), 0.4417 (miR-106b~25).  
D LNA anti-miR-130b, -miR-301a, miR-19a (to inhibit miR-17-92 cluster members) and miR-15b (to 
inhibit miR-15-16 cluster members) were used separately and combined. [3 LNA combination: anti- 
miR-130b, -miR-301a, and miR-19a; 4 LNA combination: anti-miR-130b, -miR-301a, miR-19a, and 
miR-15b]. Bars represent means (SD) of at least three independent experiments performed in 
triplicate. P values vs. scrambled LNA control (One-way ANOVA test): *P<0.05: 3 LNA combination: 
0.0424 ; 4 LNA combination: 0.0500). 
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Figure 14. Validation of miRNAs displaying significant differential expression in NSCs vs. Diff-NSCs. 
Q-PCR single assay validation of NSC expression of the top 15 DE miRNAs listed in Table 2. Results 
for each miRNA are expressed as the log2 fold change relative to NSC expression of the 
endogenous control gene U6. Bars represent the mean (SD) of three independent experiments. P 
values vs. U6 control (Mann–Whitney U test): **P<0.01: 0.0058 (miR-15b-3p), 0.0092 (miR-335-3p), 
0.0069 (miR-15b-5p), 0.0074 (miR-16-2-3p), 0.0078 (miR-16-1-3p), 0.0099 (miR-15a-3p); *P<0.05:  
0.029 (miR-92a-1-5p), 0.0204 (miR-130b-5p), 0.022 (miR-130a-5p), 0.031 (miR-25-5p), 0.037 (miR-
93-3p), 0.042 (miR-301a-5p), 0.021 (miR-130b-3p), 0.019 (miR-106b-5p), 0.032 (miR-19a-3p). 
 
 
 
Quantitative PCR-ChIP assays were then performed on NSCs before and after differentiation to 
quantitatively assess Foxm1 recruitment and histone H3 acetylation (AcH3) at the promoter region 
of each miRNA gene putatively targeted by Foxm1. The 15 microRNAs were either transcribed 
singularly or as part of a cluster (Table 2), in case of a cluster for further experiments expression 
levels of one representative miRNA are reported.  For all miRNAs tested Foxm1 recruitment was 
higher in the NSCs when compared to Diff-NSC. Attention was focused on the cases where 
transcriptional activation of these promoters, as evidenced by AcH3, was significantly more intense 
in NSCs than in Diff-NSCs (Fig. 13B-C). Foxm1 recruitment indeed was statistically significant for 
miR-130b, miR-301a, and miRNAs belonging to the miR-15~16 and miR-17~92 clusters (Fig. 13B).  
The results of the previous experiments pointed to miR-130b, miR-301a, and miRNAs of miR-15~16 
(n=4) and miR-17~92 clusters (n=2) as particularly important mediators of Foxm1’s effects in NSCs. 
This conclusion was supported by the effects observed in the cells after locked nucleic acid (LNA)-
mediated depletion of these miRNAs. As shown in Figure 13D, the NSCs’ capacity for neurosphere 
formation was not significantly reduced by anti-miR knockdown of any single miRNA or miRNA 
cluster. However, it was significantly impaired by combined depletion of miR-130b, miR-301a, and 
miR-19a (3 LNA combination). The additional depletion of miR-15b (4 LNA combination) resulted in 
an equally significant impairment of neurosphere formation.   
To investigate mechanisms underlying the stemness-promoting effects of this miRNA network, 
genes targeted by the ChIP-confirmed miRNAs listed in Table 2 were explored.  A miRTarBase 
(http://mirtarbase.mbc.nctu.edu.tw/) search returned validated murine targets for only three of these 
miRNAs: miR-15b-5p, miR-130b-3p, and miR-92a-3p (Supplementary Table 4). Thus requiring, the 
extension of the search to the literature on each miRNA, focusing specifically on validated or putative 
target genes (in any species) whose downregulation could explain the combined effect of these 
miRNAs in NSC self-renewal.  
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The results that emerged reiterated the importance of p53 signalling, whose loss/suppression is 
essential for the maintenance of embryonic stem-cell pluripotency (Hong, H. et al. 2009; Kawamura, 
T. et al. 2009). Of particular interest was a report showing that miR-130b-3p regulates CD133+ 
tumour-initiating cells in human hepatocellular carcinoma by targeting TP53INP1 (Ma, S. et al. 2010), 
which encodes a downstream component of the p53 signalling pathway. Previous work of the 
laboratory showed that Trp53inp1 expression in murine cerebellar NSCs is also suppressed by 
microRNAs of the miR-17~92 cluster, and the upregulated expression of these miRNAs was 
attributed to signalling through the Hh-Gli-Nanog axis (Garg, N. et al., 2013). In light of the current 
findings, p53 signalling in these cells also appears to be under the control of a second miRNA 
network, this one regulated by Foxm1. In support of this hypothesis, mirSVR prediction scores 
provided by microRNA.org (http://www.microrna.org/microrna/home.do) indicate that murine 
Tp53inp1 is a very likely target of miR-130b (mirSVR score: -0.0029). The same applies to miR-
301a, another Foxm1-regulated microRNA belonging to the miR-130b family (mirSVR score: -
0.0030). The Foxm1-regulated miRNA network that modulates p53 signalling might also comprise 
miR-92a-3p, whose validated targets include Trp63, another member of the p53 family of 
transcription factors. Because of the high-level sequence homology that characterizes these 
transcription factors, p63 and p73 are capable of transactivating p53-responsive genes, thereby 
causing cell cycle arrest and apoptosis (NCBI).  
 
A role for Nanog in Foxm1 regulation  
Interestingly, members of the miR-17~92 cluster are components of both the Nanog-regulated (Garg, 
N. et al., 2013) and Foxm1-regulated miRNA networks, but this was the only commonality observed. 
This evidence indicates that Nanog and Foxm1 activate largely non-overlapping cohorts of miRNAs 
to ensure suppression of p53 signaling in cerebellar NSCs. How these two networks interact to 
achieve this goal is unclear. Interestingly, Nanog has been identified as a target of Foxm1 (Wang, 
Z. et al. 2011; Xie, Z. 2010). To determine whether this relation might be reciprocal, the Foxm1 
promoter region was re-examined for evidence of Nanog binding sites. As shown in Figure 15A, 
four putative binding sites for Nanog were found -3790 to -3277 bp upstream from the Foxm1 TSS. 
(For details, see Supplementary Information-Section 1). 
ChIP experiments (Fig. 15B) demonstrated endogenous Nanog at these four sites in both NSCs and 
Diff-NSCs. However, pre- and post-differentiation occupancy rates were significantly different only 
at s2–s3, where the higher Nanog occupancy in NSCs was associated with greater activation of 
Foxm1. To further elucidate the relation between these two transcription factors, dual luciferase 
reporter assays was performed in 293T cells transfected with Foxm1 wild-type promoter or an s2- or 
s3-defective mutant promoter (Fig. 15C). Ectopic expression of Nanog in these cells resulted in 
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substantial activation of the wildtype promoter, whereas luciferase activity was appreciably reduced 
in the absence of s2 in the promoter and even more so by the deletion of s3, suggesting that this 
site is required for Nanog binding onto the Foxm1 promoter.  
Taken together, these results indicate that the Hh-Gli-driven miRNA networks regulated by Nanog 
and Foxm1 are characterized by bidirectional crosstalk, which might conceivably allow more finely 
tuned, combinatorial regulation of cerebellar NSC self-renewal. 
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Figure 15. Foxm1 promoter occupancy by Nanog. 
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A Schematic of the Foxm1 promoter showing putative Nanog-responsive elements (s1; s2 and s3 
which are fairly close to one another and s4). 
B qPCR-ChIP assay of endogenous Nanog occupancy of the Foxm1 promoter region in NSCs and 
Diff-NSCs. Immunoprecipitation with anti-acetyl-H3 antibodies was used to identify Foxm1 
transcriptional activation. Eluted DNA was PCR-amplified with primers for Nanog binding sites s1, 
s2-s3, s4. Results are expressed as fold induction values relative to input controls.  Bars represent 
means (SD) of three independent experiments. P values vs. Diff-NSCs (Mann-Whitney U test): 
**P<0.01: 0.002572 (s2-3, AcH3); ****P<0.0001: 0.00000718 (s2-3, Nanog), 0.0001051 (s1, AcH3), 
0.00004356 (s4, AcH3); NS: 0.4531 (s1, Nanog), 0.7118 (s4, Nanog).  
C Luciferase activity induced by ectopic expression of Nanog and PCDNA (negative control) in 293T 
cells transfected with luciferase vector carrying the wild-type Foxm1 promoter (wt) and its mutant 
lacking the Nanog binding sites s2 and s3 (mutants s2, s3). Results are normalized to pRL-CMV-
Renilla luciferase (R-Luciferase). Bars represent means (SD) of at least three independent 
experiments, each performed in triplicate. P values vs. indicated controls (Mann–Whitney U test): 
*P<0.05: 0.01849; ***P<0.001: 0.0002265; NS: 0.08604. 
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Discussion   
 
The main goal of this study was to characterize new molecular Hh-related mechanisms responsible 
for maintaining stemness features in cerebellar NSCs. These results permit the  proposal of a model 
where Hh-Gli signalling controls the self-renewal of murine NSCs through the transcription of a series 
of microRNAs. As shown in Figure 16, two stemness miRNAs networks are described, via Nanog 
and via Foxm1, that partially overlap in our system and shed light to the role of Foxm1 in NSCs self-
renewal. Hereby identifying the transcription factor Foxm1 as transcriptionally regulated by Hh 
through Gli 1 and 2 and Nanog. These results expand the list of known downstream effectors in the 
canonical Hh-Gli signalling pathway, as well as the list of molecules capable of activating Foxm1.  
Foxm1 is an activating transcription factor that plays a role in several different cellular contexts. In 
human epidermal stem cells, Foxm1 sustains the balance between self-renewal and terminal 
differentiation (Gemenetzidis, E. et al., 2010). Foxm1 is known to regulate neuronal precursor 
induced mitosis (Gemenetzidis, E. et al. 2010), as well as several stem cell-like properties. It is 
required for proper execution of mitosis and this is highlighted by the fact that Foxm1 knockout is 
embryonically lethal (Wierstra, I. 2013). It has been reported that Foxm1 upregulates the expression 
of the neural stemness marker Nestin1 in NSCs from the embryonic cerebral cortices of mouse and 
is critical for their self-renewal (Wierstra, I. 2013).  Mutants conducted with loss-of-function Foxm1 
suggest that in the murine cerebellum its main function is the adjustment of the transition in G2 / M 
phase (Schuller U. et al, 2007; Gage, F.H. 2000). All previous studies did not however provide 
information regarding Foxm1’s regulation or other functions in cerebellar NSCs.  
Previous works of the laboratory reported Hh-related miRNAs involved in the maintenance of 
cerebellar NSCs (Ferretti, E. et al, 2008, Garg, N. et al, 2013). The present study has allowed to 
identify, through mRNA- and miRNA-sequencing, a series of Foxm1-controlled miRNAs highly 
expressed in NSCs. As a result, miR-130b, miR-301a and the clusters miR-17~92 and miR-15~16 
were identified as direct transcriptional targets of Foxm1. Combined knock-down of these 
microRNAs leads to a significant decrease in terms of NSC abilities to form neurospheres. Such 
results show how microRNAs are fundamental for the self-renewal of these cells, through mediating 
the effects of Hh signal.   
Subsequently, Foxm1-miRNAs were analysed. In support of this hypothesis, one of these miRNAs, 
miR-130b, has already been correlated with pro-proliferative effects in NSCs (Gong, X. et al., 2013) 
and that one of its target is Trp53inp1, a molecule involved in p53 pathway. 
Also, the miR-17~92 cluster is part of the miRNA network, whose expression is required for the 
expansion of cortical NSCs in vivo (Bian, S. et al., 2013). Previous investigations of the group 
identified miR-17~92 cluster members as direct targets of signaling through the Hh-Gli-Nanog axis 
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and important regulators of NSC self-renewal (Garg, N. et al, 2013).  This study demonstrated that 
these miRNAs are also components of the Foxm1-miRNA network.  
In previous works it has been reported that Foxm1 regulates Nanog expression (Wang and Park et 
al., 2011; Xie, Z. 2010, Wierstra, I. 2013), and the presented data of this thesis have shown that 
Foxm1 itself is transcriptionally activated by Nanog, leading to a positive feedback regulation. It is 
evident from the proposed model that a crosstalk between Gli, Nanog and Foxm1 exists.  
Moreover, Garg et al reported the maintenance of NSC self-renewal via the Gli-Nanog-miR-17~92 
axis by counteraction of p53 inhibition of Gli and Nanog, through Trp53inp1 regulation. The dual 
suppression of Trp53inp1 via miR-17~92 cluster (Hh-Nanog- and Hh-Foxm1-microRNAs) and miR-
130b (Hh-Foxm1-microRNAs alone) suggests a convergence, also partially overlapping on p53 
pathway control. This convergence could suggest the possibility of some functional redundancy that 
could be part of a cellular protection mechanism in case of a gene mutation affecting key components 
of the regulatory network. 
In the present work, it is demonstrated that miR-15~16 is part of the miRNAs regulated by Foxm1 
and it cooperates to maintain the undifferentiated status of NSCs. In support to this hypothesis, a 
role for miR-15a has been described in neuronal context. It has been shown that the high expression 
of miR-15 appears to be involved in neuronal maturation in MeCP2-deficient adult-born new neurons 
(Gao, Y. et al., 2015). So, in cerebellar NSCs context it could act as a regulated of the balance 
between pro- and anti-stemness cues, mediating the effect of Hh-Gli-Foxm1 axis.  
In conclusion, this project presents an in depth investigation of the Hh pathway in the context of the 
cerebellar NSCs. In addition, a new molecular mechanism Gli-Nanog-Hh-related that participates in 
the maintenance of the stemness features of these cells was described. The identified network is 
composed of a downstream effector of the Hh-Gli signalling, Foxm1, and a series of microRNAs 
transcribed by itself. It has been demonstrated how the Hh-Foxm1-microRNAs axis is involved in the 
fine-tuning of pro-proliferative and pro-apoptotic cues in these cells. 
Based on the results of this study that identified Foxm1 as a downstream effector of the Hh-Gli 
signalling, and due to the high similarity of the human and mouse promoter regions of Foxm1, Foxm1 
could be a major player and should be taken into consideration in future investigations regarding not 
only mouse but also human cells. 
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Figure 16. Regulation of cerebellar NSCs self-renewal by the Hh-Foxm1-miRNA axis. 
The tumour-suppressor p53 checks NSC self-renewal directly, by activating Trp53inp1, and by 
inhibiting Gli and Nanog. Increased Hh-Gli signalling promotes NSC self-renewal by inhibiting p53 
and upregulating Nanog expression. Our data show (bold-face type) that it also upregulates the 
expression of Foxm1 (directly and indirectly via Nanog). These two transcription factors activate the 
expression of several miRNAs that target Trp53inp1. Silencing of Trp53inp1 allows expansion of the 
NSC pool by promoting proliferation and diminishing apoptosis. Its loss also disrupts a feedback loop 
that maintains high p53 levels, thereby diminishing the tumour suppressor’s ability to repress Gli and 
Nanog expression. 
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Methods 
 
Murine cerebellar NSC cultures 
Cerebellar NSCs were isolated from P4 wild type black 6 /C56 (C57BL/6) mice (n=8 per group) and 
cultured, as previously described 3. In brief, freshly dissected cerebella were placed in HBSS 
supplemented with 0.5% glucose and penicillin-streptomycin and dissociated, mechanically and 
enzymatically. The cells were maintained as mycoplasma-free neurosphere cultures in selective 
stem-cell medium consisting of serum-free DMEM-F12 supplemented with 0.6% glucose, insulin 25 
mg/ml, N-acetyl-L-cysteine 60 mg/ml, heparin 2 mg/ml, B27 supplement without vitamin A, EGF 20 
ng/ml, and bFGF 20 ng/ml. To induce differentiation, the cells were transferred for 48 h to 
differentiation medium consisting of the medium described above, prepared without the EGF/bFGF 
and supplemented with platelet-derived growth factor (PDGF; 10 ng/ml) (Sigma, P3076). 
Mycoplasma contamination was excluded by routine screening with the PCR Mycoplasma Detection 
Kit (ABM, Cat. No. G238). The neurosphere-forming cells from these cultures were selected and re-
plated in the same medium, where they gave rise to new neurospheres, thereby confirming the 
capacity for self-renewal. Animal experiments were performed according to the European 
Community Council Directive 2010/63/EU and were approved by the local Ethical Committee for 
Animal Experiments of the Sapienza University of Rome. 
 
Experimental and analysis design 
Overview of study design 
NSCs (n=3) and Diff-NSCs (n=3) were subjected to RNA (mRNA-seq) and small-RNA (microRNA-
seq) sequencing. A consensus-based approach was used to analyse the mRNA-seq dataset, in 
order to overcome any methodological bias inherent in specific alignment and differential expression 
tools. Two different tools were used for mapping and alignment, and three different approaches were 
used for the differential expression analysis. The intersection of all three methods resulted in 
common genes with similar expression changes (Supplementary Table 5). The expression values 
reported by the DESeq algorithm were used for the remaining analysis as representative of all 
methods. The common genes were used as input for the pathway enrichment analysis using DAVID 
(david.ncifcrf.gov). Potential downstream targets of the Hedgehog (Hh) pathway were taken under 
further consideration (Fig S1). 
In parallel, the microRNA-Seq dataset was analysed using the DESeq2 algorithm to detect 
differential expression of microRNAs between NSCs and Diff-NSCs (Fig S1). Subsequently, from 
the list of up regulated microRNAs in NSCs, the binding sites of the highest expressed gene 
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implicated in the Hh pathway were searched in the promoter region of the microRNAs. Then, the 
candidate Transcription Factors (TFs) were validated and the network connecting the TFs and 
microRNAs was created (Fig S1). 
 
 
 
Figure S1. Experimental and analysis design. 
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mRNA- sequencing  
Library preparation and RNA sequencing 
RNA extraction. Total RNA was extracted from NSCs and Diff-NSCs using Trizol reagent (Life 
Technologies, USA). Quality-control assays were performed on an Agilent BioAnalyzer using the 
RNA Nano Kit (Agilent # 5067-1511). Only RNAs with RIN values > 9 were used for library 
preparation. The standard Illumina protocol and TruSeq RNA Sample Prep Kit were used to 
construct the mRNA-seq libraries. The mRNA in 400 ng of total RNA was converted into a library of 
template molecules suitable for deep sequencing analysis. All samples were sequenced using the 
Illumina Genome Analyzer IIx. 
 
Mapping and differential expression analysis of RNA-seq reads 
Transcriptome mapping with Genomatix Mining Station and differential expression analysis with 
Genomatix Genome Analyzer (Method 1) 
All 70mer paired-end sequenced reads were aligned to the latest version of the Mus musculus 
genome available at the time, (NCBI38/mm10), using the Genomatix Mining Station (GMS, Sesame 
2.4, https://www.genomatix.de/). All samples were quality-controlled with the FastQC tool 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) before mapping, and an average of 
75% of reads with a quality score >30 was obtained. In terms of annotation, the read distributions 
for NSCs and Diff-NSCs were similar (Fig. S2B), confirming the absence of biases in sequencing 
and normalization.  
Differential expression analysis with Genomatix Genome Analyzer 
The RNA-Seq sequenced samples were subjected to differential expression analysis using the 
DESeq method in the Genomatix Genome Analyzer platform (GGA, v3.30126, 
https://www.genomatix.de/). Differentially expressed transcripts were selected as those exhibiting a 
minimum log2 fold change of 1 and adj. P-value < 0.05 (P-value adjusted with multiple testing 
correction using the Benjamini and Hochberg method). 
 
Transcriptome mapping with TopHat and differential expression analysis with Cuffdiff 
(Methods 2 and 3) 
Mapping of RNA-Seq reads 
All sequenced 70mer paired-end reads were aligned to the Mus musculus genome (NCBI37/mm9) 
using the spliced read aligner TopHat version v1.3.1 3.  Two iterations of TopHat alignments have 
been made to maximize the use of splice site information derived from all samples. 
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RNA-Seq transcriptome assembly 
The transcriptome of each sample was assembled separately from the mapped reads using Cufflinks 
V1.2.1 5 with default parameters and the UCSC reference annotation. Transcript abundance was 
estimated as fragments per kilobase of exon per million fragments mapped (FPKM). 
Analyses of the transcript distributions after TopHat mapping and Cufflinks assembly among different 
samples, biological replicates and cell types exclude the presence of biases in sequencing and 
normalization (Fig S3B, S3C and S3D). The samples displayed similar proportions of alternatively 
spliced genes. Transcribed isoforms not annotated in the reference version of the UCSC were found 
in all samples (1100-1500 per sample). Clustering analysis of the expression data confirmed clear 
separation of NSCs from their respective Diff-NSCs and the similarity of biological replicates within 
each group (Fig S3F).  
The RNA-Seq reads were processed using two variations of the same protocol: the standard whole-
read protocol (Cuffdiff-WR, Method 2), as well as the variation of this protocol based on the analysis 
of trimmed reads (Cuffdiff-TR, Method 3).  The motivation for the trimmed reads approach is based 
on the observation that some NSC samples had comparatively lower average base quality towards 
the end of the reads. By trimming all datasets to 55bp reads, mappability has been enhanced by 
eliminating low-quality bases, and avoiding mapping artifacts across samples, by ensuring a 
consistent read length. Additionally, the follow-on impact on differential expression analysis was 
tested by using these trimmed reads. 
Comparison of the differential expression results from all different methods 
After analysing our samples with three different methods, the intersection of the results was selected, 
which yielded 988 DETs (Supplementary Table 5). Comparing the expression among the three 
different algorithms, the Pearson correlation was confirmed between the DESeq method and Cuffdiff, 
and it was extremely high. Additionally, the ANOVA test was performed to verify that the values 
obtained using the DESeq method are representative of the other two methods (p-value=0.9567, no 
statistically significant differences among means and standard deviations). The Pearson correlation 
and ANOVA test were performed using GraphPad Prism version 6 (La Jolla, CA, USA, 
http://www.graphpad.com/). In conclusion, the three approaches show a high degree of synergy and 
that results are not affected by methodological bias, alignment artefacts, or sequence quality. For 
downstream analyses, the expression values obtained from the DESeq algorithm were selected as 
representative of all methods. 
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Functional Analysis  
The Database for Annotation, Visualization and Integrated Discovery (DAVID, david.ncifcrf.gov) was 
used for functional annotation, Gene Ontology categories with a Bonferroni correction adjusted p-
value < 0.05 were reported10. 
 
Clustering analysis 
Clustering and heat maps were generated in Gene-E (version 3.0.238, 
http://www.broadinstitute.org/cancer/software/GENE-E/) (Supplementary Figure 2 for better 
visualization) and in R (http://www.r-project.org/) (the rest of the figures) using differentially 
expressed transcript levels as input. In Gene-E, the one minus Pearson correlation method was used 
for clustering and the complete linkage as a linkage method whereas in R the Bray-Curtis method 
and the average linkage were used in hclust to cluster the samples and heatmap.2 to generate the 
heat maps. 
 
miRNA-sequencing 
microRNA library preparation and sequencing 
Small RNA-seq libraries were prepared in accordance with Illumina's TruSeq Small RNA Sample 
Prep Kit protocol. 
 
Mapping of microRNA-seq reads and differential expression analysis with DESeq 
Mapping of microRNA-seq reads 
All sequenced single-end reads (31 bases) of the three biological replicates for each cell type (NSC 
and Diff-NSC) were controlled with FastQC 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) before mapping and they showed an 
average of 89% of reads with a quality score >30. All samples were aligned to the Mus musculus 
small RNA library (12-2013), (miRBase V20) using the Genomatix Mining Station (GMS, Sesame 
2.4, https://www.genomatix.de/). The microRNA-seq read distributions for the NSCs and Diff-NSCs 
are shown in Figure S5B.  
microRNA-seq reads and differential expression analysis 
The microRNA-seq reads were analysed for differential expression in NSCs vs. Diff-NSCs in the 
Genomatix Genome Analyzer (GGA, v3.30126, https://www.genomatix.de/) using the DESeq2 
method. Differences characterized by a minimum log2 fold change of 1 and an adjusted p-value of 
< 0.05 (Benjamini–Hochberg correction for multiple testing) were selected for further analysis.  
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Identification and characterization of binding sites in promoter regions  
The MatInspector tool in the Genomatix Genome Analyzer was used to identify putative binding sites 
in the Foxm1 promoter for Gli and Nanog (Supplementary Information – Section 1. The Foxm1 
promoter region) and putative Foxm1 binding sites in the promoters of miR-130b, miR-301a and 
representative members of miR-17~92 and miR-15~16 clusters (Supplementary Information – 
Section 2. The miRNA promoter regions). Occupancy of the Foxm1 promoter by endogenous Gli1, 
Gli2, and Nanog in NSCs and Diff-NSCs was assessed by real-time qPCR-ChIP assay.  Anti-acetyl-
H3 antibodies were used to identify transcriptional activation of Foxm1. 
 
mRNA-Seq mapping statistics 
mRNA-seq data were analysed with the Genomatix Mining Station (GMS) (Genomatix GmbH, 
Münich, Germany) and TopHat/Cufflinks. Mapping statistics for the two methods are summarized in 
Figures S2A and S3A, respectively. The number of reads per biological replicate that could be 
aligned to the mouse genome and the transcript distributions were similar with the two methods, 
thereby excluding the presence of biases in sequencing and normalization (Fig S2-3). 
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Figure S2. mRNA-seq mapping statistics with Genomatix Mining Station. 
A. Mean (SD) number of reads successfully aligned to the mouse genome, transcriptome, and exon 
junctions for each NSC and Diff-NSC sample. 
B. Average distribution of reads mapped to the genome for NSC and Diff-NSC samples. 
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Figure S3. mRNA-seq mapping statistics with TopHat and Cufflinks assembly. 
A. Mean (SD) number of reads successfully aligned to the mouse genome, transcriptome, and exon 
junctions for each NSC and Diff-NSC sample. 
B. Box plots showing FPKM values (median [IQR]) for NSCs and Diff-NSCs.  
C-D. M-A plots for the (C) NSC and (D) Diff-NSC replicates showing the expression ratio (M) of each 
transcript as a function of its average abundance. 
E. Compositions of the NSC and Diff-NSC transcriptomes.  
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F. Unsupervised hierarchical clustering of all samples using all expressed transcripts. Nodal 
numbers indicate bootstrap values obtained by resampling the data 10,000 times. 
 
Differentially expressed transcripts  
A total of 988 DETs were identified with all three methods (Fig. S4). Pearson correlation analysis 
disclosed strong correlation between the DET expression values obtained with DESeq and those 
generated with the other two methods (DESeq vs. Cuffdiff-WR: r=0.985, P value=0.00; DESeq vs. 
Cuffdiff-TR: r=0.997, P value=0.00). ANOVA confirmed that the DESeq expression values were 
reliably representative of the others (P value=0.9567), and they were therefore used for subsequent 
analyses of the 988 DETs. 
 
 
Figure S4. Transcripts displaying differential expression (DETs) in NSCs and Diff-NSCs. 
Venn diagram of DETs identified with DESeq, Cuffdiff-WR, and Cuffdiff-TR.   
 
microRNA-seq mapping statistics 
The mapping and read distribution results allowed us to proceed with the differential expression 
analysis without fear of bias from the sequencing and mapping (Fig S5).  
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Differentially expressed microRNAs 
Using the DESeq2 algorithm, 1893 differentially expressed (DE) miRNAs were identified, of which 
80 were statistically significant. In detail, 40 miRNAs were up-regulated and 40 were down-regulated 
in NSC in respect to Diff-NSC (Supplementary Table 3). Hierarchical cluster of these 80 miRNAs 
is reported in Figure 13A. 
 
Figure S5. MiRNA-seq mapping and DE analysis statistics. 
A. Alignment of microRNA-seq mapping reports the Total number of reads and hits are classified as 
Ignored, Ambiguous, Insufficient, Multiple and Unique (Millions). 
B. Percentages of unique, multiple and insufficient hits among microRNA-seq reads for NSCs and 
Diff-NSCs.  
 
Neurosphere-forming assay 
Neurospheres grown in the stem-cell-selective medium were dissociated to single cell through 
dissociation solution non-enzymatic buffer (Cod: C5789, Sigma-Aldrich). Viable cells were counted 
after Trypan-blue exclusion and re-plated at clonal density (1-2 cells/mm²) in 96-well plates 
containing stem-cell selective medium. Results were expressed as the percentage of cells plated 
that formed neurospheres (neurosphere-forming cells NFCs). 
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Immunofluorescence 
Neurospheres were placed in Cell Dissociation Solution Non-enzymatic 1x (Sigma-Aldrich,) to obtain 
aggregates of around 5-10 cells. The latter were plated on poly-lysine-coated Lab-Tek chamber 
slides (cover slips) and allowed to adhere for 3 h or differentiated for 48 h, as described above, to 
detect differentiation markers. Cells were fixed with 4% paraformaldehyde for 20 min at room 
temperature and incubated in blocking solution (5% normal goat serum (NGS), 1% BSA, 0.1% Triton 
X-100). Cells were incubated overnight with primary antibodies diluted in blocking solution and for 2 
h with secondary antibodies. Primary antibodies were rabbit anti-Nanog polyclonal (Abcam 
ab80892); mouse anti-Nestin (Abcamab 11306); mouse anti-Gli1, #2643 (Cell Signaling Technology 
Inc); mouse anti-parvalbumin P3088 (Sigma); rabbit anti-S100 S2644 (Sigma); mouse anti-b-III 
tubulin MAB1637 (Millipore); rabbit anti-Foxm1 (Santa Cruz Biotechnology, sc-502).  Secondary 
antibodies (488-conjugated anti-mouse and anti-rabbit) were purchased from Molecular Probes 
(Invitrogen). Nuclei were Hoechst-counterstained and cover slips were mounted with fluorescence 
mounting medium (S3023) (Dako). Images were acquired with a Carl Zeiss microscope (Axio 
Observer Z1) using Apotome technology and AxioVision Digital Image Processing Software. 
 
Immunoblotting assay 
Cells were lysed in Tris–HCl pH 7.6, 50 mM, deoxycholic acid sodium salt 0.5%, NaCl 140 mM, 
NP40 1%, EDTA 5 mM, NaF 100 mM, Na pyrophosphate 2 mM, and protease inhibitors. Lysates 
were separated on an 8% acrylamide gel and immunoblotted using standard procedures. 
Membranes were blocked for 1 h at room temperature in 5% nonfat dry milk and incubated overnight 
at 4 °C with the following antibodies: rabbit anti-Foxm1 (Santa Cruz Biotechnology, sc-502), rabbit 
anti-Hsp70, (Santa Cruz Biotechnology, sc-33575), mouse anti-βIII Tubulin (MAB 1637 Millipore), 
goat anti-actin I-19 (sc-1616; Santa Cruz Biotechnology), anti-Nanog Antibody (PA1-41577, Thermo 
Fisher). HRP-conjugated secondary antisera (Santa Cruz Biotechnology) were applied and binding 
visualized by enhanced chemiluminescence (ECL Amersham). 
 
RNA isolation and quantitative RT-PCR 
RNA was isolated from cells, as previously described (Ferretti, E. et al., 2006). The High Capacity 
cDNA reverse transcription kit (Applied Biosystems Life Technologies, ThermoFisher) was used to 
synthesize cDNA, as previously described (Ferretti, E. et al., 2009). 
Quantitative reverse transcription (RT–PCR) analysis was performed using a High Capacity cDNA 
Reverse Transcription kit. mRNA expression was analysed on cDNAs using the ViiA™ 7 Real-Time 
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PCR System, SensiFAST™ Probe Lo-ROX (Bioline), TaqMan gene expression assay according to 
the manufacturer’s instructions (Applied Biosystems). Each amplification reaction was performed in 
triplicate, and the average of the three threshold cycles was used to calculate the amount of 
transcripts in the sample (SDS software, AB). mRNA quantification was expressed, in arbitrary units, 
as the ratio of the sample quantity to the calibrator or to the mean values of control samples. All 
values were normalized to 2 endogenous controls: ß-2-MICROGLOBULIN and HPRT. 
MiRNA expression was assessed with Taqman probes, as previously described, 25 using the 
following miRNAs: miR-15b-3p (Code: 002173), miR-92a-1-5p (Code: 464504_mat), miR-130b-5p 
(Code: 002460), miR-130a-5p (Code: 462691_mat), miR-335-3p (Code: Mm03307393_pri), miR-
25-5p (Code: PM12401), miR-93-3p (Code: PM12787), miR-15b-5p (Code: 000390), miR-16-2-3p 
(Code: 462713_mat), miR-301a-5p (Code: 006346_mat), miR-130b-3p (Code: 000456), miR-106b-
5p (000442), miR-16-1-3p (Code: 002489), miR-15a-3p (Code: 002488), miR-19a-3p (Code: 
000395). 
 
PCR for Foxm1 isoforms 
cDNA from NSCs was used to discriminate Foxm1 isoforms. PCR was performed according to the 
manufacturer’s protocol (GoTaq® DNA Polymerase, Promega), using the following isoform-specific 
primers: 
Forward primer           5’-CAAGCCAGGCTGGAAGAACTC-3’ 
Reverse primer  5’-GTTCACTGGGAACTGGATGGG-3’ 
PCR products were separated on 2% agarose gel. 
 
 
Statistical analysis of in vitro experiments 
Unless otherwise indicated, statistical analyses were performed with StatView 4.1 software (Abacus 
Concepts). The Mann–Whitney U test for unpaired data was used to analyse differences in gene 
expression between NSCs and Diff-NSCs and the unpaired T-test, paired T-test and one-way 
ANOVA were used where appropriate. Results are expressed as means (S.D.) from at least three 
experiments. 
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Luciferase-reporter assays 
293T cells purchased from ATCC (Milan, Italy) were seeded into 24-well plates and transfected 24 
h later with mouse Foxm1 promoter luciferase vector (1457 bp) (Genecoepia, Catalogue No. : 
MPRM26630-PG02, Gene Accession: NM_008021). Transfection was done with Lipofectamine® 
2000 Reagent (Invitrogen) and included 80 ng of the Foxm1 promoter luciferase vector, 400 ng of 
inductor (Nanog, Gli1, Gli2, or (as a negative control) PCDNA), and 2 ng of CMV-Renilla Luciferase 
control vector. Cells were harvested 24 h post-transfection and tested with the dual-luciferase assay 
(Promega). Results were expressed as firefly / Renilla luciferase activity ratios (F-luc/R-luc) and 
represent means (SD) of at least three experiments, each performed in triplicate. Foxm1 promoter 
luciferase vector was used to generate, by site-directed mutagenesis, the mutant derivatives lacking 
Nanog-binding sites. 
 
Site-directed mutagenesis 
The QuickChange Multi Site-Directed Mutagenesis Kit (Agilent Technologies) was used to 
mutagenize Foxm1 promoter construct by deleting critical nucleotides in Nanog-binding sites s2 and 
s3. The reaction was carried out with the following primers: 
NBS2 Fw: CGGCTTTACTGTCCTAAGTCAAGAAAATAAACAAAGTTATCACAGGAG 
NBS3 Fw: GGTTTCCCTCTCTTCTGTTAACAGATCTTACACCGC.  
 
Chromatin immunoprecipitation (qPCR-ChIP assay) 
ChIP was performed using the MAGnify™ Chromatin Immunoprecipitation System (Invitrogen). 
Briefly, for each ChIP reactions 300000 cells were used, the cells were cross-linked 10 min with 1% 
formaldehyde and the reaction was stopped with 0.125 M glycine for 10 min at room temperature. 
Cells were washed and harvested, and membranes were lysed with Lysis Buffer and Protease 
Inhibitors (200X) for 5 min on ice. Chromatin was fragmented to obtain chromatin fragments of about 
400–600 nucleotides.  After sonication, the samples were spun at 10000 rpm at 4°C for 10 minutes 
to pellet the cell debris.  The primary antibody was coupled for 1 h to the protein A/G Dynabead, at 
the same time the lysate samples were diluted in Dilution Buffer/Protease Inhibitor (200X).  After 1h 
the lysates were added to their respective antibody/beads for 2 h. After which the lysates were 
washed three times with IP Buffer 1 and twice with IP Buffer 2. After the final washing, the cross-
linking was reversed with Reverse Crosslinking Buffer and proteinase K at 55°C for 15 minutes and 
then the DNA was purified and precipitated. Eluted DNA was PCR amplified with primers 
encompassing the Gli- and Nanog- responsive sites of murine Foxm1 promoter. The following 
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antibodies were used: rabbit polyclonal anti-Foxm1 C-20 (Santa Cruz Biotechnology, code: sc-502), 
rabbit polyclonal anti-Gli1 2553 (Cell Signaling), rabbit monoclonal anti-Nanog (Cell Signaling, code: 
8600), rabbit polyclonal anti-Gli2 (Santa Cruz Biotechnology, code: sc-271786x), rabbit polyclonal 
anti-acetyl-histone 3 (Millipore, code: 06599). Eluted DNA has been analysed with Q-PCR. Primers 
were designed with Primer-Blast designing tool (http://www.ncbi.nlm.nih.gov/tools/primer-blast/) (Ye, 
J. et al. 2012) and Primers tool (Genomatix Genome Analyzer, GGA, v3.30126, 
https://www.genomatix.de/). 
 
Foxm1 promoter Fw:  5'-GCCACGTAACCGCAAGTCTA-3' 
Foxm1 promoter Rev:  5'-CTACCCACTCGGTTACCCCT-3' 
 
Primers for miR-301a upstream region (RT–qPCR) 
Site miR 301a Fw:   CAGACGCTTTGGAAAAGGAG 
Site miR 301a Rev:  GCTAACATGGGCATCATAAAAA 
 
 
Primers for miR-130b upstream region (RT–qPCR) 
Site miR 130b Fw:   TGTAATGCTTCCGAGTAGGTAGGA 
Site miR 130b Rev:  CCCCCAAAGGGCTTTAGCT 
 
Primers for miR-335 upstream region (RT–qPCR) 
Site miR 335 Fw:   GCGTTCAGAAGCTCTGTCCT 
Site miR 335 Rev:  GCCACAACTACCAGCTTCGT 
 
Primers for miR-16-2 upstream region (RT–qPCR) 
Site miR 16-2 Fw:   GGAGCCATCGCTGAGTATAAAAA 
Site miR 16-2 Rev:  CCGTTTAGGCTCAGCAAAATTT 
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Primers for miR-15a upstream region (RT–qPCR) 
Site miR 15a Fw: CCATTGGGAGGTGAAGGAAGGA 
Site miR 15a Rev: GAACAAGAGCACGGGCTCCTTA 
 
Primers for miR-130a upstream region (RT–qPCR) 
Site miR 130a Fw:   GGGTCATGGAAATGAGTGTGAA 
Site miR 130a Rev:  GCCACCGGTTCCTGTCTATC 
 
Primers for miR-17 Bs2-3upstream region (RT–qPCR) 
Site miR 17 Fw:   GACTGCTGGGTCTGGAGAAG 
Site miR 17 Rev:  TGTGCTGCCCAAATGTAGAA 
 
Primers for miR-106 Bs4 upstream region (RT–qPCR) 
Site miR 106 Fw:   CCCCTTGGAAGACAGAATGA 
Site miR 106 Rev:  GGGTTCAACTTTCACCGTGT 
 
Primers for Gli s1-5 upstream region (RT–qPCR) 
Site Gli s1-5 Fw:   GACGCTCCGTCACGTGACCG 
Site Gli s1-5Rev:  CAGCGCCGCTTTCAGTTGTTCC 
 
Primers for Gli s6-8 upstream region (RT–qPCR) 
Site Gli s6-8 Fw:   GAGCCGCGTGGACTGAG 
Site Gli s6-8 Rev:  CAGTGGTCGACTTCCTTCCG 
 
Primers for Nanog s1 new upstream region (RT–qPCR) 
Site Nanog s1 Fw:   CACCGGCCTCTAACTTGTTC 
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Site Nanog s1 Rev:  AGGGAGCACAGAATGAGATGA 
 
Primers for Nanog s2-3 upstream region (RT–qPCR) 
Site Nanog s2-3 Fw:  AGAAAGAACGGCTTTACTGTCCT 
Site Nanog s2-3 Rev:  CGCAGCCTCCTGTGATAACT 
 
Primers for Nanog s4 upstream region (RT–qPCR) 
Site Nanog s4 Fw:   GAGGCCCTTTTGTCTCACAC 
Site Nanog s4 Rev:  TTTGAAGGAACCCGGTTAGA 
 
Knockdown studies 
Small-interfering-RNA knockdown of Foxm1 was performed in NSCs with ON-TARGETplus 
SMARTpool (L-057933-01-0005) and control ON-TARGETplus Non-targeting siRNA knockdown (D-
001810-02-05) (Dharmacon). Hiperfect reagent (Qiagen) was used for transfections. Cells were 
harvested for assay 72 h post-transfection. 
Knock-down of miRNA expression was done with miRCURY LNA™ miRNA inhibitor (Exiqon, miR-
130b-5p: code 4101000-011; miR-301a-5p: code 4101560-011, miR-15b-3p: code 4101249-011, 
miR-19a-3p: code 4101300-101), individually or in combination, and a scrambled control, referred to 
as LNA ctrl (Exiqon mirCURY knockdown probe control A: code 199002-08) (Exiqon). Hiperfect 
reagent (Qiagen, Hilden, Germany) was used to transfect the siRNA constructs into NSCs. The final 
concentrations were 10 nM (for single transfection) and 50 nM (for combination transfections).  
 
Validated targets of miRNAs 
The validated miRNA targets reported in were identified with miRTarBase 
(http://mirtarbase.mbc.nctu.edu.tw/) (Chou, C.-H. et al. 2015), where each Foxm1-regulated miRNA 
was used as input. 
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Putative miRNA target genes 
MicroRNA.org (http://www.microrna.org/microrna/home.do) database was queried for putative 
miRNA target genes, where miRNA-target interactions were predicted with miRanda 3.3a and scores 
were calculated with mirSVR (good mirSVR score less than or equal to -0.1). 
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Supplementary Information: 
 
Foxm1 promoter (mouse) 
ttgtacaaaaaagcaggcttcgaaggagatagaaccagatcttggaattcTGGCTAGCCTGGGGCTGGCAATGTAGA
CCTGGCTGGCCTGGAATTCAGAGATCTGCCTGCCTCTGCCTCCTGGGTGCTGGAATTAAAGG
TGTGCACCACCACACTCTGCTCACTCTTCAAACACAGTCTTATTATGTAGCCCAGACTAGACT
AATGTGAGGCCCTTTTGTCTCACACCAGGATTATTGGTACGTGCCACATACCTAGCTGCTTAC
AACTTCTAACCGGGTTCCTTCAAATATTAAATAAGAACAAAATTCAGAAAGGCGAAGACCCTGC
CTCCTGTCTCATAGCATACCACACTCACTACATCTTAGGCCTTTGTATTCAGCAGGCCTCCTC
CCGGTCAAAGCAGCTCTCCCTTCTCTATTTACTTCAGGGTTTCCCTCTCTTCTGTGTAATGGG
TAACAGATCTTACACCGCGTTCTCAGCTCCTTTAAAAAAAAAAAAAGGAAAGAAAGAAAGAAC
GGCTTTACTGTCCTAAGTCAAGATCTCATTAAAATAAACAAAGTTATCACAGGAGGCTGCGGG
AGGGCGAGCCAGTGACCCCGGCTACTCCGAAGGCGGAAACACGAGGATCCAGAATTCTACA
CAACCTTGTGTCAGACAAAACCCACCGGCCTCTAACTTGTTCCTCTGTAGCTAGAATTCTACC
GATCTGTTCATCTCATTCTGTGCTCCCTCGCCATCAGACGCTGAGGCCAGGGGGAGGACGCC
CGGGTCCGCCGCTGTATCCTCCGCTCTTATCGTAAAGTACTTCGAGGGAATAAACGATCGTC
CGGACACCTCGGGGGCTGGGGCCCGGGAGGAGGCGGCCACAGACCGGAGCGGGGCGGAG
CCACGTAACCGCAAGTCTAGGGCCAGAAACCCAAGCCGGACCCCACGGAGCCGCGTGGACT
GAGCGGGGCGGGGGACCCAGGGGTAACCGAGTGGGTAGCCAGCCCGGGGAAGTGGCGTA
CGCTGTCCCGGAACTGCTGGCCGCCGTCCGCGCGTCCCCGCGTCCCTCCCGCCGCCCCTC
GAGCCCCGCCGGGGCCGCCTTACCCGCCCTCCCGGCCGCGGCCGCCGCTCCTCAGGACAC
CGAGCGTTCGGGGCCGGAACCCGGAGACAAGCCGGTGCCGATTGGCGACGCTCCGTCACG
TGACCGCAACGCTCCGCCGGCGCCAATTTCAAACAGCGGAACAACTGAAAGCGGCGCTGCG
GGACCCACCCCCGGCCCGGGCTCCCCCGTCACCCCGCCCCGGGCTCCCACCCCGGCCGTC
CCGCCGGGACCCGCCGCCCGGGCCCGGCTCGGCCCCGCGTGGAGCAGACGCGGCCTGTG
AGGTGAGTGGGGTGCGGCCGGGTCCAGGGAGGGCTCGGAGTCGGCACTGCCGGGGCTGTG
GGGCGCGAGGGGGTGTTGGGCACCGCCGGGAAGAAGGTCTGAGCCTCCGGCCTCGGCCTT
GCCGCCGCCGTGTTCTCCGAGCATCCCCGGACCCTGGGAACAGGCCTGCCCTCGGAGTCTG
CATTTGCAGTCAACCCTGCCTCCGCCTCCACCGCTGCAGGGCGGGATCCTGGCTGAGTGTTG
GTTGCAAGGTTCCCTGTTGAGTGTGGAGAATAATGGGGTCGTGGGGTGG 
 
 
Provided below is the sequence (50 nt) upstream of the promoter for mouse Foxm1. 
5'-ttgtacaaaaaagcaggcttcgaaggagatagaaccagatcttggaattc-3'  
 
 
Putative binding sites for GLI: 
5'-cggaCCCCacggagc -3’ 
 
Putative binding sites for NANOG: 
5'-ggtggtAATGagacaccta-3’ 
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3’-taggtgtctCATTaccacc-5' 
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Foxm1 weight matrix for putative binding sites using the Genomatix Genome Analyzer: 
5'-AACA-3' 
3'-TGTT-5' 
 
Cluster miR-15b~16-2 
miR-16-2 promoter region 
chr=3, start=69032759, end=69033359 
 
CAGTTCTAAGCCAGGAGGAGCTTGAGGCAATCAAGAATCCAGAGTCTATAACAAATGAAATTG
CACTTTTGGAAGCTCAGTGTCGTGAAATGAAACCAAACCTTGGAGCCATCGCTGAGTATAAAA
AAAAGGTGTGAGTGAATTGTTTCTAGTAGAAATTTTGCTGAGCCTAAACGGGGTATTTAATTGT
GCATAATGACCAGTGCTAATTCTCAGATTTGTATGTGTGTGAAAGGGTTTTGTTTTTTTGTTTTA
CAATCTTCACAGGAAGATTTATATTTGCAAAGAGTAGCCGAACTGGACAAAATTACTTCTGAAA
GAGATAATTTTAGACAAGCATATGAAGATCTTCGAAAACAAAGGCTGAATGAATTTATGGCTGG
TTTTTACGTAATAACAAATAAACTAAAAGAAAACTACCAGATGCTCACATTGGGAGGAGATGCT
GAACTGGAGCTTGTGGACAGTTTAGATCCTTTTTCTGAAGGAATCATGTTCAGGTTGGTGAGA
TTTTAATCCTGCATCTTTTCCAAACTACTATTTCTTTAGTGTGTGAAGGTTGGAACTACATTTAT
TTGGTAATAACTATCTTGCTCTTACA 
 
miR-130a-3p promoter region 
chr=2, start=84741545, end=84742145 
 
GGTGGGAGGAGGCTGGAGGGGGAAGCACAGAGGAAGAGCTCCCAAATGAAATTCAGGCCTC
CATTTTTCCTGCTTGTTGCAATGGGGGTGGGGGGTGGTCTCCCTGAGGCTACTCCATGGTCT
GAATGGATCTCCACAGGGAGGAGCCTTGCAGTCTCTGTCCCTTAGGTTAGAGCTGTAACTGG
CTTCTGACCAGTATGCTTAGCTGCTGTGTGACTCTAGAGGCCTGCATGGCTCTGAGCCTTGG
GTTTCAAGTGCACCTGGCTTTGGAATTTTATCAGTCTCTATTGTCCTCAATGAAATTAAGGGGG
ATGGCCTGGGGTCATGGAAATGAGTGTGAAGACTCCACTACTAAACCCTTGGGATAGACAGG
AACCGGTGGCTTCTAAGCCCAGTGTCAATGAGAGCTTATCCTTAACTCAAGAGCCAAATCACT
GGCCATTTCGCTTAATACCATATCCATAGAGTACTTTGAAGACATCAGAAAGGAAACAGTGGG
GTTTCAGTTGCTTGCACCTCCAGATCTGGGAGCTTCTTTCTCCTGCCTAAGCACCTGTAGTTA
GGTTCCATTATTCTAGACCTGGAGGTCACCTGAGATCAT 
 
Cluster miR-17~92 
chr=14, start=115045026, end=115045626 
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AAAGATGGCAAACTGATGGTCAGTAGAGTGACAGGTACACATGACACTCGAGTGCTGGGTCT
GGAGAAGCTGCAGTTAGTATTTAGGATAACAGTATATATAATATATAGTTCTACATTTGGGCAG
CACAGTTGGTTTCAGGCTATGAATAAAAATCATTGGAGTGAAACCTAAAGAAAAGTAAAATTAA
TAAGGAAGAGCTGCTAAAATCAGGTTTAAGCTGACACTATCTACAGAGCTAAAGTTTTCCATAA
TATGTTGCTTTTTTTAAAAGAAATGCAAGAAGCTGACTGATGGATCCCTGAGCTGCCAGGTAA
GGATTCCACAGGCCTGGGTTTGATTGTGAGTGACCAGAATTGTACAATTATTACTAAAACAGA
AACATAGTCACTTCTGACTCCATTCTTAACATTTTTGGATTAAAACTTGTTTCAGATGACTAATG
AAAACTTCCTTTAAAACGTGATAAAGCTCTAATGTCAGCACGATCCACATGATCCATGTGCCTC
CTATAAAGGGAGGGGTCTGTCACCAGTGTTACGGATTGAATGCTACGTTTATCTTCCAACATA
GGAAGCCTGCCAGGTACTTTCTTCAATAT 
 
miR-335-3p promoter region 
chr=6, start=116405759, end=116406359 
 
AAATCAAGCAGGGTCAGGTAACAGGTGAGTATATGGGCCGTGAGGTGAGTGCTGTACACAGG
TCCTGGGGACTGAGGTTCTGGGGTTTAGAGCTCTGTTTCCTGAGAGAGCAGAGTAAACTACA
TTGAGAACACTTCCTGCTCCTTTTGGGGAGGGAGGACTTGATGAGTCAGAAATGTACAGAGT
GGTTGTGGGCGTTCAGAAGCTCTGTCCTGCTTCCTTCTGACATGAGACCTCCTGATGAGCTAA
CTGAGTCTCCCCTGCAGGAATCCTAGAGTGGCCTTTCTGGACGAAGCTGGTAGTTGTGGCCA
TCGGCTTCACTGGAGGACTTCTCTTTATGTATGTTCAGTGCAAGGTGTACCTACAGTTATGGA
AAAGACTCAAGGCTTACAATAGAGTGATCTATGTTCAGAACTGTCCAGAAACAAGTAAAAAGA
ATATTTTTGAAAAGTCTGCACTTACAGAGCCCACCCTTGAAAATAAAGAAGGACATGGAATGT
GTCATTCCACCACAAATTCTTCTTGCACAGAGCCTGAAGACACTGGAGCAGAAATTATTAACG
TCTGACCATGTGAGGGTGTCATTTCCTTGATGTCCACC 
 
Cluster miR-106b~25 
chr=5, start=138171718, end=138172922 
 
TCTTAAGTGCCTGTCCCAACTCTACTCACCGGGAAAGCAGCTCCAGAAGGCTGAAAGGAGAG
ACGTTTTCTAAGGTTGTGGCCACCAAATAGAGCCCACTGTGTCTGATGTGAATAAAATGACGA
TCACCGTGATACTGAGGCAGAGTTGAGGACAGAGGCCATTAAGAAAAGACCAGAATTGTAGT
AAGGAAACCTGCAAGATGGCACCCTGAGGTCTACTAGTGATGGGCGATGCCCCAGATCTAAG
ACCTGGCCGCCTAACGTGGAAAGGTAGTATCTACCTCTCAAAGTTGTTGATAGTCAAAAAATA
GGGTGCATGGCTCTGTAACTGGCTTCTTGTTAGTACTCAAAACATTTATAAACAAATCCTCCCC
ACACACACACCCCCGCCCCCAAGCTTCCTACCAAGCTGCCCTTGACAGGGAGGAGGCACTCA
CCCACCTCCACAGTTCTAAGGCCCTGCACACCAACCACAGTAGTTACCATGACAACCGGGGA
CTCGCCTCCAGGCAGTCCCGTCAGCTTCCGGTAGAAGAGCTCTGCCACATCACGACCACCAC
TGTCCCCGCGGACTAGCCAGGTGGAAAGATAGTTAAGGAACAGGCGACACAGACTGATCTGG
ATTCGATTTCTACCCAGCTACCCTACCCCGTCTCCCGGGTCAAAGGATACAGTCTTTATAGAT
GAGCGGATCCCCCTTGGAAGACAGAATGAAGAACTGGGAAATCATGGCGGTTCTGGAGGATA
GACGAGAACACGGTGAAAGTTGAACCCACCCCGCCTTGTGGACGCGGAACAAAAGGCCGCA
CGGAGGCTGGCGCTTTAAGAAACACTCCTCCCACACACACACTCGCGAGCATTAATTTCGAA
CCGCGGGAAACAGGGTGTCCAACCCGCCAGGATCTGGCAATCTTTCAACGGCCCGCCCTCA
AGCCCCTTGTCATTCAATCTAGACTCGTCCATTGATTGGTTAAAGTTAGGGGCTGGCAGCAGT
TGGGAACCCCCTATCTGATTGGCGGGTTCTCAGCCGCACGGGTCACATGGGTGACGACGTTT
56 
 
CGCGCCAATTTCGGTTGGCCGGCTACGTCCCGCCGCGCGTTCGTTTTCTGCTTCCCCAGAGA
GAGATTTTTGAGCCCTTCAAGTCCTGCCACACCGTCCCCGGCAGCGATGGCGCTTAAGGACT
ACGCGATCGAAAAAGGTGAAGAT 
 
miR-130b promoter region 
chr=16, start=17121616, end=17122216 
 
AATATAGCTAGAATTACATAGGAGACCTTGTCTCAAAAAACAAGCAAAAGAAGTGGTCAGGAC
ATGATCTGGAGAGGGATGTGTGTAATGCTTCCGAGTAGGTAGGAAACTCAGAGGGTGCAAAA
GCCAGAGCTAAAGCCCTTTGGGGGGCAGAAGGAAGTCCTTTTGGATATTATCTTAGTGAACTG
GAAAGTAGATTCAATTACCAGGGCGGTCTGGTAGGGCAGAGTATGGAGGGAACTGCAAACTG
GGAGAGGGCTGGGTGCTTTGAAACGGAAAGGACCACGGCTCAGAAGGAGGTCAAAATCCAG
GAGCTCAAAATCCAGAAGGTACCTGGGTGCCTTTGGCGGTCACAGTGAGGGGTGGAGCAGT
GGGGGCGGGGTGGGGTGGGGAGCACACCAATGCGCATGCCTAGAGAAGTGAGCATTGTTAC
GCGTACTGGTGCTGGACCCGCCCCCTGTCTCTGTGGGCATTCATTCCCTGGGGTAGACCGG
GAGGGGGGTGGGTAGTCTGGGGATCTGGAGTCTGCACTGCGGCTGTAGGGAGAGAGTGGG
TACGCCCTGCAGTCCTCATCCCGATGGTTTCCCATCACCTTTCTCAG 
 
miR-301a promoter region 
chr=11, start=86926083, end=86926683 
 
TTTTCATTTGTTTTTTGAAGTAATTACTCAAAGGACTTGTTTTCTATGGTAGGTAACCCAGACGC
TTTGGAAAAGGAGTTAACCAACATTACATTTAGGCAAAAAACATAGTTTTTCACATATTTGCCTT
AGTAGTAATTACAGCTGATTTTGTTAATATCAATTATAAAGTTTTTATGATGCCCATGTTAGCTA
CTAAAGGCTCAGGACATATTACAAAATTCCTTTACATCTGTGCATGTTTATGTCTGAATGCTGC
TAATTTCAGGTTAGTCAACAAAAACCAATTATCACTTTGGTCCTTTGCCCTTCCAAAAATATACT
GGTATAAATGTTTTTAGGTTTTGGATGTCTTCTGACTAAAATGGCAACTCAACTTTAAGGTCTTT
GCACACTGAGCCTTGCATTCCTTTCCTGCTCACTCCTGCTAACGGCTGCTCTGACTTTATTGC
ACTACTGTACTTTACAGCGAGCAGTGCAATAGTATTGTCAAAGCATCCGCGAGCAGGTTGCAC
ACCTTTCCTGGTTCTTGTCTTACATCTTCAGTATTTGTGAAAAGGTTTCTATAACTTTCAGTGTG
GAAAACTGTATAATTTTGTTA 
 
cluster miR-15a~16-1 promoter region 
miR-15a promoter region 
chr= 14, start= 61619651, end= 61620251 
 
CCTATAGTTTTGGCATTTGAATGGTAGAGTTGGCAGAATGAGAAGTTCAATTTGTCTTCAGCTA
TATAAGGTTGACATTAAGCTAGCCTATAGAGAACCCCATACCCCCAAAAGAAAAAGTCTTTGTT
TTATAAGTTGTGGCCTACCAACTTTCAAAGTATAGGACACGATGCATTCTCAGATATCCTGGTT
TATAGTAGTTTTGTTTTTTGTTTGTTTGCTCCTTGAGGCAGGGTCTTTGTAGTACTGCCTGGCC
TGGGACTCACTATGCTGAAAAAGCTGTCCTGGAATTCATGAAGTCTTCTAGCAAGGAAGTTGG
ACGTGATTATTTTTGTCTCCTAAGAGTAAAGAATATCTAAATCAAATAGCAATAAGAATGGAACT
GATCCTGAAGCAAAGTGATACCTGCGTGTATCCTAGCCATTGGGAGGTGAAGGAAGGAAGTG
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GGAAACAGCATATCAAGGTAAAAAACTTGGAACATTATTAAGATAGAAAGGAGGTATAAGGAG
CCCGTGCTCTTGTTCTGGAAGGTGACGGTGATGTTACTGAAGGATGAGAAACCACCTGAAAC
ACTGAGCCTTCTCACAATATTACATTTGAA 
 
Supplementary Information – Section 2. The miRNAs promoter regions. 
 
 
 
Tables: 
Table 1. Gene Ontology categories over-represented in the set of 988 DETs. * 
Gene Ontology Category Fold Enrichment Count % Bonferroni-corrected P-value 
Cell cycle 5.4 37 4 2.50E-15 
DNA replication 8.1 15 1.6 1.50E-07 
p53 signaling pathway 3.8 14 1.5 9.00E-03 
ECM-receptor interaction 3.4 15 1.6 1.70E-02 
* Findings are ranked according to Bonferroni-corrected P values 
 
Table 1. Gene Ontology categories over-represented in the set of 988 DETs. 
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Table 2. MiRNAs with putative Foxm1 binding sites that are most markedly upregulated in NSCs. 
No. MicroRNA log2 fc * adj. P-value 
Member of 
microRNA Cluster 
Part of microRNA 
Family 
ChIP-
confirmed 
1 mmu-miR-15b-3p 2.75 2.33E-07 15b~16-2 15a, 15b, 16-1,16-2, 
195a 
Yes 
2 mmu-miR-92a-1-5p 2.56 3.66E-04 17~92 25, 92a-1, 92a-2, 92b Yes 
3 mmu-miR-130b-5p 1.97 6.72E-04 - 130a, 130b, 301a, 
301b 
Yes 
4 mmu-miR-130a-5p 1.98 1.54E-03 - 130a, 130b, 301a, 
301b 
No 
5 mmu-miR-335-3p 2.66 2.27E-03 - - No 
6 mmu-miR-25-5p 1.58 2.77E-03 106b~25 25, 92a-1, 92a-2, 92b No 
7 mmu-miR-93-3p 1.49 2.77E-03 106b~25 17, 18a,18b, 20a, 
20b, 93, 106a, 106b 
No 
8 mmu-miR-15b-5p 1.6 3.88E-03 15b~16-2 15a, 15b, 16-1,16-2, 
195a 
Yes 
9 mmu-miR-16-2-3p 1.71 7.46E-03 15b~16-2 15a, 15b, 16-1,16-2, 
195a 
Yes 
10 mmu-miR-301a-5p 1.95 1.08E-02 - 130a, 130b, 301a, 
301b 
Yes 
11 mmu-miR-130b-3p 1.69 1.14E-02 - 130a, 130b, 301a, 
301b 
Yes 
12 mmu-miR-106b-5p 1.82 1.19E-02 106b~25 17, 18a,18b, 20a, 
20b, 93, 106a, 106b 
No 
13 mmu-miR-16-1-3p 1.96 1.76E-02 15a~16-1 15a, 15b, 16-1,16-2, 
195a 
Yes 
14 mmu-miR-15a-3p 1.48 1.89E-02 15a~16-1 15a, 15b, 16-1,16-2, 
195a 
Yes 
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15 mmu-miR-19a-3p 1.82 3.91E-02 17~92 17, 18a,18b, 20a, 
20b, 93, 106a, 106b 
Yes 
* NSC vs. Diff-NSC 
Table 2. The miRNAs with putative Foxm1 binding sites that are most markedly upregulated in 
NSCs. 
 
Supplementary Table 1. Putative and validated downstream mediators of Hh-Gli signaling. 
Gene Title Reference Context 
Ang-1 Sonic hedgehog (Shh) 
regulates the expression of 
angiogenic growth factors in 
oxygen-glucose-deprived 
astrocytes by mediating the 
nuclear receptor NR2F2 
Li, Y. et al, 2013 Astrocytes oxygen-glucose 
deprivation (OGD) could 
induce the expressions of 
Ang-1 with the expression of 
Shh signaling components 
increased.  
Ang-2 Sonic hedgehog (Shh) 
regulates the expression of 
angiogenic growth factors in 
oxygen-glucose-deprived 
astrocytes by mediating the 
nuclear receptor NR2F2 
Li, Y. et al, 2013 Astrocytes oxygen-glucose 
deprivation (OGD) could 
induce the expressions of 
Ang-2 with the expression of 
Shh signaling components 
increased.  
BCL2 Activation of the BCL2 
Promoter in Response to 
Hedgehog/GLI Signal 
Transduction Is 
Predominantly Mediated by 
GLI2 
Regl, G. et al, 
2004.  
GLI2 activating the 
prosurvival factor BCL2, may 
represent an important 
mechanism in the 
development or maintenance 
of cancers associated with 
inappropriate HH signaling. 
BMI1 Sonic hedgehog regulates 
Bmi1 in human 
medulloblastoma brain 
tumor-initiating cells 
Wang, X .et al 
2012. 
In human medulloblastoma 
brain tumor-initiating cells, 
Gli1 preferentially binds to the 
Bmi1 promoter, and Bmi1 
transcript levels are increased 
and decreased by Gli1 
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overexpression and 
downregulation, respectively. 
BMP4 Hedgehog signaling restrains 
bladder cancer progression 
by  
eliciting stromal production of 
urothelial differentiation 
factors 
Shin, K. et al, 
2014. 
In bladder cancer decreased 
Bmp4 expression resulting 
from loss of Hh signaling may 
account for the accelerated 
rate of tumor progression 
observed in mice with ablated 
Smo function. 
BMP5 Hedgehog signaling restrains 
bladder cancer progression 
by  
eliciting stromal production of 
urothelial differentiation 
factors 
Shin, K. et al, 
2014. 
In bladder cancer decreased 
Bmp5 expression resulting 
from loss of Hh signaling may 
account for the accelerated 
rate of tumor progression 
observed in mice with ablated 
Smo function. 
bmp6 Expression of indian 
hedgehog, bone 
morphogenetic protein 6 and 
gli during skeletal 
morphogenesis 
Iwasaki, M. et 
al., 1997. 
During skeletal 
morphogenesis Gli 
surrounded the ihh domains 
and bmp6 was expressed 
immediately adjacent to ihh. 
Ccna1 Sonic hedgehog controls 
growth of external 
genitalia by regulating cell 
cycle kinetics 
Seifert, A.W. et 
al, 2010. 
In external genitalia loss of 
Shh causes a transient 
downregulation of G2 / M 
promoting genes and a 
sustained decrease in the 
expression of genes that 
govern the G1 / S transition. 
Ccna2 Purmorphamine Induces 
Osteogenesis by Activation 
of the Hedgehog Signaling 
Pathway 
Wu, X. et al, 
2004.  
In osteogenesis, at early time 
points (24 hr), 
purmorphamine treatment led 
to the upregulation of cell 
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cycle control genes, including  
Cyclin A2 (3.5-fold). 
Ccnb1 Hedgehogs tryst with the cell 
cycle 
Roy, S. and 
Ingham, P.W., 
2002.  
Barnes and  colleagues  
unexpectedly  identified  
PTC1  amongst  prey that 
associate with a bait 
mimicking phosphorylated 
cyclin B1. 
CCNB2 Hedgehog signaling pathway 
and gastric cancer 
Katoh, Y. and 
Katoh, M., 2005. 
In gastric cancer  FOXM1  is   
reported  to  be upregulated  
by  the  Hedgehog  signaling 
and  induces  transcriptional  
activation  of CCNB2  gene  
encoding Cyclin B2. 
Ccnd1 Hedgehogs tryst with the cell 
cycle 
Roy, S. and 
Ingham, P.W., 
2002.  
Examination   of   the   status   
of   D-type   cyclins,   central 
regulators   of   G1   phase   
progression,   revealed   that,   
upon incubation  with  SHH,  
the  CGNPs  preferentially  
upregulate cyclin D1 RNA 
and cyclin D1 protein. 
Ccnd2 Hedgehogs tryst with the cell 
cycle 
Roy, S. and 
Ingham, P.W., 
2002.  
Examination   of   the   status   
of   D-type   cyclins,   central 
regulators   of   G1   phase   
progression,   revealed   that,   
upon incubation  with  SHH,  
the  CGNPs  preferentially  
upregulate cyclin  D2 RNA. 
Ccne1 Hedgehogs tryst with the cell 
cycle 
Roy, S. and 
Ingham, P.W., 
2002.  
These effects of modulated 
HH signalling on the 
proliferation patterns of eye 
cells are mirrored by 
corresponding alterations in 
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the levels of cyclin  E 
transcript  and  protein.   
Ccne2 Hedgehogs tryst with the cell 
cycle 
Roy, S. and 
Ingham, P.W., 
2002.  
The effects of modulated HH 
signalling on the proliferation 
patterns of eye cells are 
mirrored by corresponding 
alterations in the levels of 
cyclin  E transcript  and  
protein.   
Cdc2a Hedgehog modulates cell 
cycle regulators in stem 
cells to control hematopoietic 
regeneration 
Trowbridge, J.J. 
et al, 2006.  
 In ptc WT,  Cdc2a  is up-
regulated but down-regulated 
in ptc-1/ cells during 
hematopoietic regeneration, 
suggesting that ptc-1/ cells 
are unable to up-regulate 
expression of these genes as 
necessary for hematopoietic 
regeneration.  
CUL7 The cullin protein family Sarikas, A. et al, 
2011.  
Cyclin D1 and insulin receptor 
substrate 1 (IRS-1) are 
potential proteolytic targets of 
the CUL7 E3 ligase. 
cyyr1 Characterization of human 
gene locus CYYR1: a 
complex multi-transcript 
system 
Casadei, R. et 
al, 2014.  
 Xu et al. indicated CYYR1 as 
a putative target gene 
regulated by Hedgehog (Hh) 
signalling during vertebrate 
development. 
ERBB Alternative splicing of the 
ErbB-4 cytoplasmic domain 
and its regulation by 
hedgehog signaling identify 
distinct medulloblastoma 
subsets 
Ferretti, E. et al, 
2006.  
Low-level Hh signalling in 
human MB is associated with 
the selective maintenance of 
high ErbB-4 CYT-1 
expression, an alteration that 
exerts tumor-promoting 
effects. 
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FGF-
(1,7,8,10) 
The Sonic Hedgehog 
Signaling Network 
in Development and 
Neoplasia 
Chari, N.S. and 
McDonnell, T.J., 
2007. 
Known Transcriptional 
Targets of Hh Signaling 
MAPK/ERK1/
2 signaling  
Regulation of the hedgehog 
signaling by the mitogen-
activated protein kinase 
cascade in gastric cancer 
Seto, M. et al, 
2009.  
PTCH expression was 
significantly correlated with 
extracellular signal-regulated 
kinase (ERK) 1/2 
phosphorylation as well as 
SHH expression in the gastric 
cancers assessed by 
immunohistochemistry. 
KRAS-MEK-ERK cascade 
has a positive regulatory role 
in GLI transcriptional activity 
in gastric cancer. 
FOXE1 Hedgehog signaling pathway 
and gastric cancer 
Katoh, Y. and 
Katoh, M., 2005.  
Forkhead-box  transcription  
factor  FOXE1 is  reported  to  
be upregulated  by  the  
Hedgehog  signaling. 
FOXM1 Hedgehog signaling pathway 
and gastric cancer 
Katoh, Y. and 
Katoh, M., 2005. 
Forkhead-box  transcription  
factor FOXM1 is   reported  to  
be upregulated  by  the  
Hedgehog  signaling. FOXM1 
gene  is  a  direct 
transcriptional target of 
Hedgehog signaling pathway, 
and FOXM1 induces  
transcriptional  activation  of 
CCNB2  gene  encoding 
Cyclin B2. 
FST  Clinical and Therapeutic 
Implications of Follistatin in 
Solid Tumours. 
Shi, L. et al, 
2016.  
Strong FST expression was 
found in basal cell carcinoma 
and seemed to be mainly 
activated by transcription 
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factor GLI2, which as a 
Hedgehog signalling 
mediator, has been shown to 
be up-regulated by the 
expression of FST. 
Gli1 SnapShot: Hedgehog 
Signaling Pathway 
Chen, M.H. et al, 
2007.  
HH responding cell: Flies and 
vertebrates may use different 
strategies downstream of 
Smo to modulate activity of 
the Ci/Gli transcription 
factors. 
Gli2 SnapShot: Hedgehog 
Signaling Pathway 
Chen, M.H. et al, 
2007.  
HH responding cell: Flies and 
vertebrates may use different 
strategies downstream of 
Smo to modulate activity of 
the Ci/Gli transcription 
factors. 
Gli3 SnapShot: Hedgehog 
Signaling Pathway 
Chen, M.H. et al, 
2007.  
HH responding cell: Flies and 
vertebrates may use different 
strategies downstream of 
Smo to modulate activity of 
the Ci/Gli transcription 
factors. 
PRKG1 
(cGMP) 
cGMP Enhances the Sonic 
Hedgehog Response in 
Neural Plate Cells 
Robertson, C.P. 
et al, 2001. 
Cells in chick neural plate 
explants respond to Shh by 
differentiating into ventral 
neural-cell types. Exposure of 
intermediate-zone explants to 
cGMP analogs enhanced 
their response to Shh in a 
dose-dependent manner.  
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Hhip SnapShot: Hedgehog 
Signaling Pathway 
Chen, M.H. et al, 
2007.  
HH responding cell: Two 
general mechanisms exist to 
downregulate Hh signaling 
after the initial response. 
Ci/Gli transcription factors are 
ubiquitinated by Cullin (Cul3) 
and HIB/SPOP complexes; 
the expression of Hh-binding 
proteins, such as Ptc and 
Hhip1, is upregulated to serve 
as a sink for extracellular 
ligand. 
IGF1 Hedgehog Promotes 
Neovascularization in 
Pancreatic 
Cancers by Regulating Ang-
1 and IGF-1 Expression in 
Bone-Marrow Derived Pro-
Angiogenic Cells 
Nakamura, K. et 
al, 2010.  
In vitro co-culture and 
matrigel plug assays 
demonstrated that PDAC cell-
derived Shh induced IGF-1 
production in BMPCs, 
resulting in their enhanced 
migration and capillary 
morphogenesis activity. 
IGF2 The Sonic Hedgehog 
Signaling Network 
in Development and 
Neoplasia 
Chari, N.S. and 
McDonnell, T.J., 
2007.  
Known Transcriptional 
Targets of Hh Signaling 
Insm1 An Integrated Approach 
Identifies Nhlh1 and Insm1 
as Sonic Hedgehog-
regulated Genes in 
Developing Cerebellum and 
Medulloblastoma 
De Smaele, E. 
et al, 2008.  
Insm1 and Nhlh1/NSCL1 as 
novel HH targets induced by 
Shh treatment in cultured 
cerebellar granule cell 
progenitors. 
Mycn Nmyc upregulation by sonic 
hedgehog signaling 
promotes proliferation in 
developing cerebellar 
granule neuron precursors 
Kenney, A.M. et 
al, 2003.  
Nmyc upregulation   occurred  
in  proliferating  neural  
precursor cells   exposed   to   
ectopic   Shh   in   transgenic   
mice  and  in 
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medulloblastomas of  Ptch 
heterozygotes.  
Nhlh1 An Integrated Approach 
Identifies Nhlh1 and Insm1 
as Sonic Hedgehog-
regulated Genes in 
Developing Cerebellum and 
Medulloblastoma 
De Smaele, E. 
et al, 2008.  
Insm1 and Nhlh1/NSCL1 as 
novel HH targets induced by 
Shh treatment in cultured 
cerebellar granule cell 
progenitors. 
Ntrk3 Sonic Hedgehog-responsive 
Genes in the Fetal Prostate 
Yu, M. et al, 
2009. 
In primary urogential sinus 
(USG) mesenchymal cells 
and in the cultured UGS Ntrk3 
exhibited Shh-regulated 
expression. 
PDGFRA Hedgehog Target Genes: 
Mechanisms of 
Carcinogenesis Induced by 
Aberrant Hedgehog 
Signaling Activation 
Katoh, Y. and 
Katoh, M., 2009. 
Hedgehog  signals  
upregulate  PDGFRA gene, 
encoding  PDGF  receptor,  to  
upregulate  ERK  signaling 
cascade in basal cell 
carcinoma. 
PDPN Significance of podoplanin 
expression in cancer-
associated fibroblasts: A 
comprehensive review 
Pula, B. et al, 
2013.  
In cancer associated 
fibroblasts podoplanin 
(PDPN)-positive A431 cells 
exhibited high expression of 
CD44 and sonic hedgehog 
(SHH), which are both 
markers of tumor initiating 
cells. 
POU3F2 Integrative genomic analyses 
of ZEB2: Transcriptional 
regulation of ZEB2 based on 
SMADs, ETS1, HIF1·, 
POU/OCT, and NF-κB. 
Katoh, M. and 
Katoh, M., 2009. 
Hedgehog signals are 
predicted to indirectly 
upregulate ZEB2 via TGFß. 
POU3F2 (BRN2) was 
coexpressed with ZEB2 in 
brain corpus callosum, spinal 
cord, and fetal brain.  
67 
 
Rac1/Rhoa Sonic Hedgehog Activates 
the GTPases Rac1 and 
RhoA in a Gli-Independent 
Manner Through Coupling of 
Smoothened to Gi Proteins 
Polizio, A.H. et 
al, 2011.  
Hh ligands induce important 
changes in the actin 
cytoskeleton that modulate 
cell motility and morphology 
through stimulation of the 
small guanosine 
triphosphatases (GTPases) 
Rac1 and RhoA in a manner 
that is dependent upon the 
heterotrimeric G protein Gi. 
satb2 Bmp and Shh signaling 
mediate the expression 
of satb2 in the pharyngeal 
arches. 
Sheehan-
Rooney K. et al, 
2013 
 We propose that Bmp 
signaling establishes 
competence for the neural 
crest to respond to Hh 
signaling, thus 
inducing satb2 expression. 
SEMA6A Sonic Hedgehog-activated 
engineered blood vessels 
enhance bone tissue 
formation 
Rivron, N.C. et 
al, 2012.  
Cyclopamine treatment 
regulated axon guidance 
molecules such as 
semaphorin 6A (SEMA6A), 
demonstrating a role for 
endogenous Hh activity in 
regulating the formation of 
vascular structures and 
lumens. 
SFRP1 WNT antagonist, SFRP1, is 
Hedgehog signaling target. 
Katoh, Y., and 
Katoh, Y. 
(2006). 
These facts indicate that 
SFRP1 is the Hedgehog 
target to confine canonical 
WNT signaling within stem or 
progenitor cells. 
Tiam-1 Sonic hedgehog signaling 
regulates actin cytoskeleton 
via Tiam1-Rac1 cascade 
during spine formation. 
Sasaki, N. et al, 
2010. 
These findings demonstrate a 
novel Shh pathway that 
regulates the actin 
cytoskeleton via Tiam1-Rac1 
activation. 
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Vegf Sonic hedgehog (Shh) 
regulates the expression of 
angiogenic growth factors in 
oxygen-glucose-deprived 
astrocytes by mediating the 
nuclear receptor NR2F2 
Li, Y. et al, 2013.  Astrocytes oxygen-glucose 
deprivation (OGD) could 
induce the expression of 
VEGF with the expression of 
Shh signaling components 
increased.  
VEGFA Hedgehog inhibition reduces 
angiogenesis by 
downregulation of tumoral 
VEGF-A expression in 
hepatocellular carcinoma. 
Pinter M et al, 
2013. 
Hh inhibition with GDC-0449 
downregulates tumoral VEGF 
production in vitro and 
reduces tumoral VEGF 
expression in an orthotopic 
HCC model. 
Wnt10a Hedgehog Target Genes: 
Mechanisms of 
Carcinogenesis Induced 
by Aberrant Hedgehog 
Signaling Activation 
Katoh, Y. and 
Katoh, M., 2009.  
In E1A-immortalized RK3E 
rat kidney cells Wnt10a is 
upregulated in volar skin 
M2SMO transgenic mice with 
Hedgehog signaling 
activation. 
Wnt10b Hedgehog Target Genes: 
Mechanisms of 
Carcinogenesis Induced 
by Aberrant Hedgehog 
Signaling Activation 
Katoh, Y. and 
Katoh, M., 2009.  
In E1A-immortalized RK3E 
rat kidney cells Wnt10b is 
upregulated in volar skin 
M2SMO transgenic mice with 
Hedgehog signaling 
activation. 
Wnt2 Hedgehog Target Genes: 
Mechanisms of 
Carcinogenesis Induced 
by Aberrant Hedgehog 
Signaling Activation 
Katoh, Y. and 
Katoh, M., 2009.  
In E1A-immortalized RK3E 
rat kidney cells  Wnt2 is 
upregulated in volar skin 
M2SMO transgenic mice with 
Hedgehog signaling 
activation. 
WNT2B Transcriptional regulation of 
WNT2B based on the 
balance of Hedgehog, Notch, 
BMP and WNT signals 
Katoh, M., and 
Katoh, M., 2009. 
Hedgehog signals should 
induce WNT2B upregulation 
through GLI family members 
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as well as FOX family 
members. 
Wnt4 Gli1 acts through Snail and 
E-cadherin to promote 
nuclear signaling by b -
catenin 
Li, X. et al, 2007.  In RTOG10 cells, a clone of 
RK3E that contains a 
tetracycline (tet)-inducible 
Gli1 allele, microarray 
analysis of these cells 
identified Wnt4 as early 
response to Gli1. 
Wnt5a Characterization 
of Wnt gene expression in 
developing and postnatal hair 
follicles and identification 
of Wnt5a as a target of Sonic 
hedgehog in hair follicle 
morphogenesis 
Seshamma, R. 
et al, 2001. 
Wnt5a is expressed in the 
developing dermal 
condensate of wild type but 
not Sonic hedgehog(Shh)-
null embryos, indicating 
that Wnt5a is a target of SHH 
in hair follicle 
morphogenesis.  
Wnt5b Wnt5a and Wnt5b exhibit 
distinct activities in 
coordinating chondrocyte 
proliferation and 
differentiation. 
Yang, Y. et al, 
2003.  
Wnt5b appears to coordinate 
chondrocyte proliferation and 
differentiation by differentially 
regulating cyclin D1 and p130 
expression, as well as 
chondrocyte-specific Col2a1 
expression. 
Wnt7b Gli1 acts through Snail and 
E-cadherin to promote 
nuclear signaling by b -
catenin 
Li, X. et al, 2007.  In RTOG10 cells, a clone of 
RK3E that contains a 
tetracycline (tet)-inducible 
Gli1 allele, microarray 
analysis of these cells 
identified Wnt7b as early 
response to Gli1. 
WNT8B Mutation and expression of 
WNT8b gene and SHH gene 
in Hirschsprung disease 
Gao, H. et al, 
2010.  
WNT8b and SHH mutations 
and abnormal expressions 
are present in the peripheral 
blood of children with 
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sporadic HSCR. These two 
genes may be related to the 
development of sporadic 
HSCR in children in the 
northeastern China. 
 
Supplementary Table 1. Putative and validated downstream mediators of Hh-Gli signalling. 
  
Supplementary Table 2. Downstream mediators of Hh signaling that are differentially 
transcribed in P4 murine cerebellar NSCs before and after differentiation.  
Gene log2 
fold 
change 
(NSC 
vs. Diff-
NSC) 
adj. p-value Function and Process (NCBI- Gene Dataset) 
Foxm1 4.81 4.21E-18 G2/M transition of mitotic cell cycle 
      cell cycle 
      negative regulation of cell aging 
      negative regulation of transcription, DNA-templated 
      positive regulation of cell proliferation 
      positive regulation of transcription, DNA-templated 
      regulation of cell cycle arrest 
      regulation of cell proliferation 
Insm1 2.98 0.0000053 cell cycle 
      cell differentiation 
      negative regulation of cell proliferation 
      negative regulation of protein phosphorylation 
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      nervous system development 
      noradrenergic neuron development 
      positive regulation of cell cycle arrest 
      positive regulation of cell differentiation 
      positive regulation of cell migration 
      positive regulation of cell proliferation 
      positive regulation of neural precursor cell 
proliferation 
Sema6
a 
1.51 0.0204 transmembrane signaling receptor activity 
      apoptotic process 
      axon guidance 
      cell differentiation 
      nervous system development 
      neuron migration 
      positive regulation of neuron migration 
Ccnb2 6.6 2.7E-27 cell cycle 
      cell division 
      growth 
      in utero embryonic development 
Ccnb1 7.39 6.63E-24 patched binding 
      cell cycle 
      cell division 
      in utero embryonic development 
      negative regulation of gene expression 
      negative regulation of protein phosphorylation 
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      positive regulation of cell cycle 
      positive regulation of cyclin-dependent protein 
serine/threonine kinase activity involved in G2/M 
transition of mitotic cell cycle 
      positive regulation of fibroblast proliferation 
      positive regulation of mitotic cell cycle 
      regulation of mitotic cell cycle spindle assembly 
checkpoint 
Ccna2 4.91 1.02E-18 cell cycle 
      cell cycle G1/S phase transition 
      cell division 
      positive regulation of fibroblast proliferation 
      regulation of G2/M transition of mitotic cell cycle 
Ccnd2 3.93 0.00000000000081
4 
G1/S transition of mitotic cell cycle 
      cell division 
      long-term memory 
      negative regulation of apoptotic process 
      positive regulation of G1/S transition of mitotic cell 
cycle 
      positive regulation of cell proliferation 
      regulation of cell cycle 
Ccne1 3.2 0.0000000178 cell division 
      negative regulation of transcription from RNA 
polymerase II promoter 
      positive regulation of cell differentiation 
      regulation of cell cycle 
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      synapsis 
Ccnd1 4.94 0.00002 cell division 
      negative regulation of cell cycle arrest 
      negative regulation of transcription from RNA 
polymerase II promoter 
      positive regulation of G2/M transition of mitotic cell 
cycle 
      positive regulation of cell proliferation 
      re-entry into mitotic cell cycle 
      regulation of G1/S transition of mitotic cell cycle 
      regulation of cell cycle 
      regulation of transcription, DNA-templated 
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Supplementary Table 3. The 80 miRNAs displaying differential expression in NSCs vs. 
Diff-NSCs. 
Up-regulated miRNAs in NSCs vs. Diff-NSCs     
miRNA log2 (fold change) adj. P-value  
mmu-miR-6399 3.85 1.37E-05 
mmu-miR-210-5p 2.87 5.18E-03 
mmu-miR-15b-3p 2.75 2.33E-07 
mmu-miR-7221-3p 2.75 1.38E-03 
mmu-miR-335-3p 2.66 2.27E-03 
mmu-miR-92a-1-5p 2.56 3.66E-04 
mmu-miR-181b-2-3p 2.42 1.24E-02 
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mmu-miR-193a-3p 2.34 1.38E-03 
mmu-miR-301b-5p 2.23 1.18E-02 
mmu-miR-29b-3p 2.10 3.95E-02 
mmu-miR-5103 2.10 1.98E-02 
mmu-miR-32-5p 2.07 2.26E-02 
mmu-miR-33-5p 2.02 4.85E-02 
mmu-miR-130a-5p 1.98 1.54E-03 
mmu-miR-503-5p 1.97 4.33E-02 
mmu-miR-130b-5p 1.97 6.72E-04 
mmu-miR-16-1-3p 1.96 1.76E-02 
mmu-miR-421-5p 1.96 6.10E-03 
mmu-miR-301a-5p 1.95 1.08E-02 
mmu-miR-7685-3p 1.91 1.97E-03 
mmu-miR-450b-5p 1.86 3.87E-02 
mmu-miR-879-5p 1.83 4.45E-02 
mmu-miR-19a-3p 1.82 3.91E-02 
mmu-miR-106b-5p 1.82 1.19E-02 
mmu-miR-16-2-3p 1.71 7.46E-03 
mmu-miR-7a-5p 1.70 1.98E-02 
mmu-miR-130b-3p 1.69 1.14E-02 
mmu-miR-6417 1.68 3.02E-02 
mmu-miR-5122 1.64 4.16E-02 
mmu-miR-126a-5p 1.62 3.96E-02 
mmu-miR-126b-3p 1.60 4.14E-02 
mmu-miR-15b-5p 1.60 3.88E-03 
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mmu-miR-25-5p 1.58 2.77E-03 
mmu-miR-345-5p 1.54 1.87E-03 
mmu-miR-3963 1.51 1.08E-02 
mmu-miR-93-3p 1.49 2.77E-03 
mmu-miR-15a-3p 1.48 1.89E-02 
mmu-miR-674-5p 1.31 4.43E-02 
mmu-miR-126a-3p 1.27 4.29E-02 
mmu-miR-5100 1.24 1.67E-02 
      
Down-regulated miRNAs in NSCs vs. Diff-NSCs     
miRNA log2 (fold change) adj. P-value  
mmu-miR-211-5p -2.90 9.01E-05 
mmu-miR-92b-5p -2.66 1.37E-05 
mmu-miR-145a-5p -2.62 4.73E-04 
mmu-miR-129-1-3p -2.61 8.65E-05 
mmu-miR-2137 -2.46 4.73E-04 
mmu-miR-187-5p -2.42 2.03E-03 
mmu-miR-92b-3p -2.42 4.73E-04 
mmu-let-7c-5p -2.34 3.66E-04 
mmu-miR-433-5p -2.34 1.98E-02 
mmu-miR-6516-5p -2.14 2.77E-03 
mmu-miR-7064-3p -2.07 2.71E-02 
mmu-miR-221-5p -2.04 4.85E-02 
mmu-let-7b-5p -2.02 8.86E-04 
mmu-miR-6546-3p -2.02 4.83E-02 
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mmu-miR-491-5p -2.00 3.88E-03 
mmu-miR-6988-5p -1.93 2.36E-02 
mmu-miR-7004-5p -1.92 1.98E-02 
mmu-miR-874-3p -1.89 1.46E-02 
mmu-miR-22-5p -1.88 8.86E-04 
mmu-miR-185-5p -1.86 1.98E-02 
mmu-miR-187-3p -1.77 3.95E-02 
mmu-miR-22-3p -1.74 6.10E-03 
mmu-miR-878-5p -1.73 2.25E-02 
mmu-miR-99a-5p -1.73 2.00E-02 
mmu-miR-185-3p -1.72 1.97E-03 
mmu-miR-3084-3p -1.72 3.83E-02 
mmu-miR-23b-3p -1.64 2.77E-03 
mmu-miR-494-3p -1.63 3.96E-02 
mmu-miR-30a-3p -1.61 5.84E-03 
mmu-miR-1249-3p -1.60 1.14E-02 
mmu-miR-153-5p -1.59 3.83E-02 
mmu-miR-470-5p -1.56 4.94E-02 
mmu-let-7k -1.53 1.98E-02 
mmu-miR-1843b-5p -1.51 4.14E-02 
mmu-miR-3083-5p -1.46 2.17E-02 
mmu-miR-146b-5p -1.45 1.67E-02 
mmu-let-7b-3p -1.39 4.14E-02 
mmu-miR-1843b-3p -1.35 3.96E-02 
mmu-miR-30e-3p -1.31 1.67E-02 
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mmu-miR-6944-5p -1.11 4.89E-02 
 
Supplementary Table 3. The 80 miRNAs displaying differential expression in NSCs vs. Diff-NSCs. 
 
Supplementary Table 4. miRTarbase: Validated murine gene targets of the Foxm1-regulated 
miRNAs. 
Target 
Gene 
Target 
Gene 
(Entrez 
Gene ID) 
miRTar
Base ID 
miRN
A 
Experiments Suppor
t Type 
Referen
ces 
(PMID) 
Acbd5 74159 MIRT59
0765 
mmu-
miR-
130b-
3p 
HITS-CLIP Functio
nal MTI 
(Weak) 
250838
71 
Arrdc3 105171 MIRT59
0623 
mmu-
miR-
130b-
3p 
HITS-CLIP Functio
nal MTI 
(Weak) 
250838
71 
Fgfr1op2 67529 MIRT59
5360 
mmu-
miR-
130b-
3p 
HITS-CLIP Functio
nal MTI 
(Weak) 
231420
80 
Homez 239099 MIRT60
0788 
mmu-
miR-
130b-
3p 
HITS-CLIP Functio
nal MTI 
(Weak) 
212583
22 
Inpp5e 64436 MIRT60
6373 
mmu-
miR-
130b-
3p 
HITS-CLIP Functio
nal MTI 
(Weak) 
212583
22 
Kdm2a 225876 MIRT58
2794 
mmu-
miR-
130b-
3p 
HITS-CLIP Functio
nal MTI 
(Weak) 
250838
71 
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Map3k12 26404 MIRT60
4876 
mmu-
miR-
130b-
3p 
HITS-CLIP Functio
nal MTI 
(Weak) 
212583
22 
Meox2 17286 MIRT00
6124 
mmu-
miR-
130b-
3p 
Luciferase reporter 
assay//qRT-PCR//Western 
blot 
Functio
nal MTI 
219412
97 
Mup13 100039089 MIRT59
2586 
mmu-
miR-
130b-
3p 
HITS-CLIP Functio
nal MTI 
(Weak) 
235971
49 
Mup7 100041658 MIRT59
2545 
mmu-
miR-
130b-
3p 
HITS-CLIP Functio
nal MTI 
(Weak) 
235971
49 
Nfia 18027 MIRT59
4100 
mmu-
miR-
130b-
3p 
HITS-CLIP Functio
nal MTI 
(Weak) 
231420
80 
Snx27 76742 MIRT58
0804 
mmu-
miR-
130b-
3p 
HITS-CLIP Functio
nal MTI 
(Weak) 
250838
71 
Tgfb1 21803 MIRT43
8308 
mmu-
miR-
130b-
3p 
Luciferase reporter 
assay//qRT-PCR 
Functio
nal MTI 
252046
61 
Timp2 21858 MIRT59
5108 
mmu-
miR-
130b-
3p 
HITS-CLIP Functio
nal MTI 
(Weak) 
231420
80 
Tmem25 71687 MIRT58
0366 
mmu-
miR-
130b-
3p 
HITS-CLIP Functio
nal MTI 
(Weak) 
250838
71 
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Ubap2l 74383 MIRT58
0136 
mmu-
miR-
130b-
3p 
HITS-CLIP Functio
nal MTI 
(Weak) 
250838
71 
              
4930444A
02Rik 
74653 MIRT59
2367 
mmu-
miR-
15b-5p 
HITS-CLIP Functio
nal MTI 
(Weak) 
235971
49 
Angel1 68737 MIRT59
2353 
mmu-
miR-
15b-5p 
HITS-CLIP Functio
nal MTI 
(Weak) 
235971
49 
Arl2 56327 MIRT00
3376 
mmu-
miR-
15b-5p 
Luciferase reporter 
assay//qRT-PCR//Western 
blot 
Functio
nal MTI 
200076
90 
Armcx6 278097 MIRT59
2342 
mmu-
miR-
15b-5p 
HITS-CLIP Functio
nal MTI 
(Weak) 
212583
22 
Bcl11b 58208 MIRT60
1136 
mmu-
miR-
15b-5p 
HITS-CLIP Functio
nal MTI 
(Weak) 
212583
22 
Bcl2l2 12050 MIRT43
8297 
mmu-
miR-
15b-5p 
Western blot Functio
nal MTI 
240706
34 
Bicd1 12121 MIRT59
2811 
mmu-
miR-
15b-5p 
HITS-CLIP Functio
nal MTI 
(Weak) 
195361
57 
Bri3bp 76809 MIRT60
1123 
mmu-
miR-
15b-5p 
HITS-CLIP Functio
nal MTI 
(Weak) 
212583
22 
Creb5 231991 MIRT58
4147 
mmu-
miR-
15b-5p 
HITS-CLIP Functio
nal MTI 
(Weak) 
250838
71 
Ddx19b 234733 MIRT59
1938 
mmu-
miR-
15b-5p 
HITS-CLIP Functio
nal MTI 
(Weak) 
235971
49 
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Dedd 21945 MIRT05
4236 
mmu-
miR-
15b-5p 
ELISA//Flow 
cytometry//Luciferase 
reporter 
assay//Microarray//QRTP
CR//Western blot 
Functio
nal MTI 
235175
78 
Dhdh 71755 MIRT57
8978 
mmu-
miR-
15b-5p 
HITS-CLIP Functio
nal MTI 
(Weak) 
212583
22 
Erlin2 244373 MIRT58
3723 
mmu-
miR-
15b-5p 
HITS-CLIP Functio
nal MTI 
(Weak) 
250838
71 
Fbxo21 231670 MIRT59
2718 
mmu-
miR-
15b-5p 
HITS-CLIP Functio
nal MTI 
(Weak) 
212583
22 
Fgd4 224014 MIRT59
9014 
mmu-
miR-
15b-5p 
HITS-CLIP Functio
nal MTI 
(Weak) 
212583
22 
Idua 15932 MIRT59
8640 
mmu-
miR-
15b-5p 
HITS-CLIP Functio
nal MTI 
(Weak) 
212583
22 
Irgq 210146 MIRT57
8443 
mmu-
miR-
15b-5p 
HITS-CLIP Functio
nal MTI 
(Weak) 
195361
57 
Itgav 16410 MIRT59
2669 
mmu-
miR-
15b-5p 
HITS-CLIP Functio
nal MTI 
(Weak) 
235971
49 
Klc1 16593 MIRT59
1288 
mmu-
miR-
15b-5p 
HITS-CLIP Functio
nal MTI 
(Weak) 
212583
22 
Lpcat2b 70902 MIRT60
3789 
mmu-
miR-
15b-5p 
HITS-CLIP Functio
nal MTI 
(Weak) 
212583
22 
Mapkap1 227743 MIRT59
2205 
mmu-
miR-
15b-5p 
HITS-CLIP Functio
nal MTI 
(Weak) 
212583
22 
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Ncl 17975 MIRT59
8105 
mmu-
miR-
15b-5p 
HITS-CLIP Functio
nal MTI 
(Weak) 
212583
22 
Pacsin2 23970 MIRT59
7925 
mmu-
miR-
15b-5p 
HITS-CLIP Functio
nal MTI 
(Weak) 
212583
22 
Rnf168 70238 MIRT57
7817 
mmu-
miR-
15b-5p 
HITS-CLIP Functio
nal MTI 
(Weak) 
250838
71 
Sorcs2 81840 MIRT59
2078 
mmu-
miR-
15b-5p 
HITS-CLIP Functio
nal MTI 
(Weak) 
235971
49 
Spsb4 211949 MIRT59
2430 
mmu-
miR-
15b-5p 
HITS-CLIP Functio
nal MTI 
(Weak) 
235971
49 
Tacc1 320165 MIRT59
2410 
mmu-
miR-
15b-5p 
HITS-CLIP Functio
nal MTI 
(Weak) 
212583
22 
Tifab 212937 MIRT60
0293 
mmu-
miR-
15b-5p 
HITS-CLIP Functio
nal MTI 
(Weak) 
212583
22 
Trim2 80890 MIRT60
0256 
mmu-
miR-
15b-5p 
HITS-CLIP Functio
nal MTI 
(Weak) 
212583
22 
              
Btg2 12227 MIRT59
6475 
mmu-
miR-
92a-3p 
HITS-CLIP Functio
nal MTI 
(Weak) 
231420
80 
Cd69 12515 MIRT59
5903 
mmu-
miR-
92a-3p 
HITS-CLIP Functio
nal MTI 
(Weak) 
231420
80 
Chm 12662 MIRT59
5805 
mmu-
miR-
92a-3p 
HITS-CLIP Functio
nal MTI 
(Weak) 
231420
80 
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Cpeb1 12877 MIRT58
4193 
mmu-
miR-
92a-3p 
HITS-CLIP Functio
nal MTI 
(Weak) 
250838
71 
Fam136a 66488 MIRT58
3677 
mmu-
miR-
92a-3p 
HITS-CLIP Functio
nal MTI 
(Weak) 
250838
71 
Gm14420 628308 MIRT59
8840 
mmu-
miR-
92a-3p 
HITS-CLIP Functio
nal MTI 
(Weak) 
212583
22 
Gm5148 381438 MIRT58
7067 
mmu-
miR-
92a-3p 
HITS-CLIP Functio
nal MTI 
(Weak) 
231420
80 
Hipk3 15259 MIRT00
2971 
mmu-
miR-
92a-3p 
Luciferase reporter 
assay//Reporter assay 
Functio
nal MTI 
175751
36 
Il5ra 16192 MIRT59
8598 
mmu-
miR-
92a-3p 
HITS-CLIP Functio
nal MTI 
(Weak) 
212583
22 
Map2k4 26398 MIRT00
7244 
mmu-
miR-
92a-3p 
Luciferase reporter assay Functio
nal MTI 
233554
65 
Mylip 218203 MIRT00
2978 
mmu-
miR-
92a-3p 
Luciferase reporter 
assay//Western blot 
Functio
nal MTI 
175751
36 
Ncam2 17968 MIRT57
8185 
mmu-
miR-
92a-3p 
HITS-CLIP Functio
nal MTI 
(Weak) 
250838
71 
Rhbdl3 246104 MIRT58
9036 
mmu-
miR-
92a-3p 
HITS-CLIP Functio
nal MTI 
(Weak) 
250838
71 
Shox2 20429 MIRT05
4792 
mmu-
miR-
92a-3p 
Luciferase reporter 
assay//immunofluorescen
ce 
Functio
nal MTI 
249275
31 
Stk10 20868 MIRT58
0680 
mmu-
miR-
92a-3p 
HITS-CLIP Functio
nal MTI 
(Weak) 
195361
57 
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Tagap 72536 MIRT59
6301 
mmu-
miR-
92a-3p 
HITS-CLIP Functio
nal MTI 
(Weak) 
231420
80 
Tagap1 380608 MIRT59
6292 
mmu-
miR-
92a-3p 
HITS-CLIP Functio
nal MTI 
(Weak) 
231420
80 
Tbx3 21386 MIRT05
4699 
mmu-
miR-
92a-3p 
ChIP-
seq//Immunofluorescence/
/In situ 
hybridization//Luciferase 
reporter assay//qRT-PCR 
Functio
nal MTI 
240689
57 
Trp63 22061 MIRT00
4280 
mmu-
miR-
92a-3p 
Luciferase reporter 
assay//qRT-PCR//Western 
blot 
Functio
nal MTI 
196086
27 
Uba1y 22202 MIRT60
1409 
mmu-
miR-
92a-3p 
HITS-CLIP Functio
nal MTI 
(Weak) 
212583
22 
Zfp300 245368 MIRT60
6063 
mmu-
miR-
92a-3p 
HITS-CLIP Functio
nal MTI 
(Weak) 
212583
22 
Zfpm2 22762 MIRT05
3813 
mmu-
miR-
92a-3p 
Luciferase reporter 
assay//qRT-PCR//Western 
blot 
Functio
nal MTI 
222670
03 
Zpbp 53604 MIRT59
5174 
mmu-
miR-
92a-3p 
HITS-CLIP Functio
nal MTI 
(Weak) 
231420
80 
              
Abbreviations: HITS-CLIP, Crosslinking immunoprecipitation coupled with high throughput 
sequencing; ELISA, enzyme-linked immunosorbent assay; Functional MTI, Functional miRNA–
target interaction;  
 
Supplementary Table 4. miRTarbase: Validated murine gene targets of the Foxm1-regulated 
miRNAs. 
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Supplementary Table 5. Transcripts differentially expressed in NSCs and Diff-NSCs 
identified by all three methods 
    log2 (fold 
change NSC 
vs. Diff-NSC) 
         log2 (fold 
change NSC 
vs. Diff-NSC) 
    
Gene DESeq CuffLi
nks 
whole-
read 
prot. 
CuffLi
nks 
trimm
ed-
read 
prot. 
Gene DESeq CuffLi
nks 
whole-
read 
prot. 
CuffLi
nks 
trimm
ed-
read 
prot. 
1700003e
16Rik 
-3.11 -3.60 -3.02 Kirrel2 3.57 3.58 3.65 
1700084c0
1Rik 
-6.79 -7.06 -7.09 Klf10 1.45 1.41 1.33 
1810058i2
4Rik 
-1.69 -1.63 -1.66 Klf11 -1.98 -1.91 -1.91 
2310022b
05Rik 
-2.45 -2.44 -2.36 Klf12 1.34 3.17 1.46 
2510003e
04Rik 
-1.48 -1.41 -1.40 Klk14 7.79 6.19 7.99 
2610318n
02Rik 
5.2 4.06 4.74 Kntc1 5.35 5.57 5.55 
2700094k1
3Rik 
2.8 2.45 2.90 Kpna2 2.65 2.39 2.56 
2810459m
11k 
-2.15 -2.51 -2.07 Lama4 Inf 6.05 5.95 
2900026a
02Rik 
-2.24 -3.07 -2.30 Lamb1 2.28 2.13 2.17 
4930427a
07Rik 
3.06 2.90 3.22 Lamb2 -1.93 -1.90 -1.81 
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4930451c1
5Rik 
-4.92 -3.62 -4.86 Lamb3 4.67 4.94 3.89 
4932438h
23Rik 
-3.76 -3.60 -3.95 Lamp2 -1.59 -1.79 -1.70 
4933407l2
1Rik 
-3.05 -3.13 -3.14 Laptm4
a 
-2.13 -2.04 -2.12 
5033411d
12Rik 
-4.52 -4.57 -4.76 Lbp -9.15 -8.43 -9.30 
5430435g
22Rik 
-4.73 -5.35 -4.75 Lbr 2.97 3.08 2.98 
6330403a
02Rik 
-5.18 -5.08 -4.79 Lcat -3.66 -3.78 -3.56 
9530053a
07Rik 
-3.03 -3.06 -3.11 Lcn2 -10.18 -6.91 -8.67 
A2m -4.56 -4.63 -4.63 Ldlr 2.38 2.29 2.32 
Aatk 2.13 2.17 2.20 Lect1 -5.37 -5.16 -4.93 
Abat -1.96 -1.94 -1.82 Lgals3 -5.5 -3.72 -5.89 
Abca1 -4.28 -4.34 -4.38 Lgals8 -1.67 -1.84 -1.70 
Abhd4 -2.31 -2.40 -2.27 Lgi4 -10.39 -9.43 -9.64 
Ablim2 -4.86 -5.29 -4.85 Lgmn -2.18 -2.16 -2.16 
Acaa2 -1.47 -1.51 -1.48 Lhx2 2.75 2.90 2.81 
Acad11 -1.97 -1.90 -1.89 Lig1 3.96 3.95 3.96 
Acadm -1.6 -1.65 -1.56 Lix1 -4.92 -5.47 -4.95 
Acap3 2.18 2.05 2.13 Lmcd1 2.82 2.81 2.86 
Acat2 1.62 1.58 1.61 Lmnb1 3.27 4.15 4.17 
Acbd5 -1.37 -5.81 -1.43 Lmo1 2.64 2.76 2.76 
Acox1 -2.16 -2.07 -2.17 Lmo3 2.19 2.59 2.16 
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Acox3 -1.66 -1.74 -1.70 Lor 5.49 4.70 5.60 
Acsf2 -3.65 -3.86 -3.59 Lpar1 -4.95 -4.75 -5.04 
Acsl6 -2.75 -2.03 -2.73 Lphn2 2.45 2.55 2.41 
Adam12 5 5.08 4.90 Lpin3 -3.42 -3.23 -3.20 
Adam19 3.26 3.42 3.40 Lrp10 -1.34 -1.36 -1.27 
Adamts14 2.65 2.52 2.66 Lrrc16a -1.37 -2.33 -1.46 
Adamts19 6.9 6.50 6.52 Lrrc2 -4.15 -4.41 -4.21 
Adamts7 2.17 2.18 2.16 Lrrc32 3.96 4.73 4.00 
Adc -4.12 -4.13 -3.96 Lrrfip1 1.69 2.14 1.77 
Adcy1 1.67 1.64 1.66 Lrrn4 5.42 5.02 5.56 
Add3 -1.37 -2.17 -1.33 Lsm4 1.68 1.56 1.82 
Adora1 -2.16 -2.36 -2.11 Lss 1.75 1.84 1.85 
Adra2a -3.96 -3.25 -3.85 Lxn -3.02 -2.96 -2.93 
Agpat3 -1.92 -2.12 -1.89 Ly6h -6.29 -5.77 -5.99 
Agt -3.14 -2.98 -3.08 Ly75 3.78 3.98 4.18 
Aldh9a1 -1.8 -2.08 -1.83 Lyn 2.77 2.61 2.81 
Alpl 3.12 3.20 3.16 Lynx1 -2.77 -2.76 -2.67 
Amotl2 -1.77 -1.72 -1.72 Lyz2 -4.45 -4.17 -4.70 
Angptl4 -8.25 -7.78 -7.56 Mad2l1 3.86 3.69 3.82 
Ank -2.47 -2.44 -2.42 Man1c1 -3.71 -3.77 -3.71 
Ankle1 6.68 7.30 6.83 Man2b
2 
-1.98 -1.91 -1.86 
Ankrd35 -4.62 -4.08 -4.18 Maoa -1.8 -1.69 -1.82 
Anln 4.12 3.81 4.50 Map1lc
3b 
-1.45 -1.83 -1.81 
Anp32b 1.44 1.93 1.86 Mapk7 1.45 2.40 1.47 
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Anp32e 1.8 1.73 1.66 March2 -2.02 -2.07 -1.92 
Antxr1 -2.14 -1.94 -2.03 Masp1 2.52 2.74 2.32 
Anxa5 -2.98 -2.93 -2.91 Mastl 3.83 3.32 3.76 
Ap3m2 -1.98 -1.97 -2.03 Mb -6.35 -7.28 -5.99 
Apitd1 3.06 3.32 3.11 Mcm10 5.55 6.30 5.52 
Aplp2 2.35 2.57 1.59 Mcm2 4.03 4.00 4.09 
Apoc1 -5.03 -5.00 -4.81 Mcm3 3.45 3.56 3.56 
Appl2 -1.54 -2.31 -1.53 Mcm4 2.35 2.47 2.36 
Aqp4 -5.91 -6.39 -5.92 Mcm5 5.04 5.19 5.10 
Arc 3.42 3.55 3.58 Mcm7 2.63 2.69 2.67 
Arhgap11a 3.43 3.45 3.45 Mdc1 2.16 2.24 2.08 
Arhgap18 2.43 2.49 2.39 Mdga1 -1.51 -1.95 -1.77 
Arhgap19 3.39 3.76 3.53 Melk 5.74 6.19 6.10 
Arhgap23 -1.91 -2.33 -1.97 Mest 2.22 2.35 2.22 
Arhgap33 1.96 3.70 2.03 Met -6.52 -6.58 -6.56 
Arhgap5 -1.53 -1.40 -1.61 Mfsd7b -3.56 -3.34 -3.58 
Arhgef10 -1.82 -1.89 -1.81 Mgll -2.69 -2.48 -2.60 
Arhgef12 -1.39 -1.46 -1.37 Mgst1 -3.17 -3.07 -3.18 
Arhgef4 -2.62 -2.67 -2.60 Mical2 3.49 3.83 3.73 
Arid5a -2.26 -2.30 -2.21 Mki67 7.11 7.22 7.22 
Armc2 -3.7 -4.03 -4.07 Mkrn1 -1.39 -1.84 -1.84 
Arsb -1.79 -1.71 -1.77 Mlc1 -1.99 -1.63 -1.93 
Asap3 -4.07 -4.11 -3.99 Mmp11 -3.99 -3.87 -3.90 
Asf1b 4.18 4.10 4.11 Mmp15 2.73 2.88 2.89 
Aspm 6.82 7.10 6.92 Mms22l 3.3 3.78 3.25 
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Asrgl1 -1.64 -1.69 -1.65 Moxd1 5.29 5.56 5.81 
Ass1 -5.39 -4.73 -4.73 Mpp3 2.86 2.81 2.76 
Atad2 3.19 3.46 3.18 Mpp5 -1.59 -1.48 -1.63 
Atad5 2.02 2.12 2.27 Mpp6 -2.16 -2.14 -1.62 
Atf3 -4.85 -4.96 -4.92 Mpv17l -2.57 -2.30 -2.23 
Atoh8 -4.39 -4.47 -4.32 Msi1 -1.83 -2.02 -1.76 
Atp1a1 -3.38 -3.29 -3.31 Mt1 -2.8 -2.53 -2.45 
Atp1a3 2.84 2.78 2.92 Mt2 -3.65 -3.79 -3.64 
Atp1b1 -3.09 -3.14 -3.10 Mt3 -3.26 -3.22 -3.19 
Atp1b2 -3.25 -3.44 -3.25 Mthfd1l 2.82 2.88 2.85 
Atp6v0a2 -2.48 -2.23 -2.32 Mthfd2 4.02 4.18 4.03 
Atrn -1.74 -2.10 -2.19 Mtmr10 -2.44 -2.13 -2.23 
Atxn1 -2.6 -2.29 -2.48 Mutyh 2.92 3.01 3.14 
Aurka 5.12 4.82 5.10 Mvp -2.79 -2.95 -2.77 
Aurkb 7.38 7.30 7.38 Mybl2 5.13 5.10 5.17 
Axl -2.71 -2.74 -2.75 Myh15 -3.22 -4.03 -3.21 
Bace2 -4.64 -4.51 -4.64 Mylk 3.93 3.23 2.23 
Bahcc1 2.3 1.77 2.33 Naaa -7.13 -7.15 -7.50 
Banf1 1.56 1.56 1.62 Naaladl
1 
4.52 4.51 4.35 
Bard1 5.25 5.35 5.08 Nacc2 -1.58 -1.72 -1.59 
Barx2 6.11 7.30 7.46 Nasp 2.12 2.02 2.06 
Bbs1 -1.74 -1.72 -1.76 Nbl1 -3.65 -3.72 -3.57 
Bc030867 3.84 3.80 3.88 Ncapd2 3 2.90 3.02 
Bcar1 -1.7 -1.94 -1.60 Ncapd3 1.68 1.86 1.63 
Bcar3 -3.92 -4.18 -3.55 Ncapg2 3.18 3.64 3.44 
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Bcas3 -1.84 -1.97 -1.84 Ncaph 4.34 4.34 4.34 
Bcat1 3.02 2.94 3.05 Ncor2 1.31 1.73 1.38 
Bdh2 -4.71 -5.12 -4.67 Ndc80 Inf 6.05 5.99 
Bex2 2.2 2.31 2.19 Ndst1 -1.44 -1.83 -1.47 
Birc5 6.02 6.28 6.36 Neat1 -2.09 -2.01 -2.09 
Bmf -4.37 -4.56 -4.49 Nebl -2.45 -2.83 -2.74 
Bmp1 -1.4 -1.77 -1.39 Neil3 8.67 8.21 8.32 
Bmp2k -3.03 -2.90 -2.70 Nek11 -6.3 -5.97 -6.24 
Bmp7 4.86 5.20 5.03 Nek2 6.6 6.67 6.33 
Bok 3.48 3.46 3.66 Nek6 -1.72 -1.67 -1.65 
Brca1 4.09 4.57 4.33 Neto1 2.64 2.73 2.65 
Brip1 4.19 4.27 3.70 Neurl1a 3.69 2.97 3.72 
Bub1 6.42 7.79 6.72 Neurl1b 4.77 4.89 4.94 
Bub1b 5.49 5.42 5.51 Nfasc -1.61 -2.24 -2.12 
C1ql1 -4.47 -4.64 -4.40 Ngef -3.51 -3.63 -3.47 
C1rl -4.71 -4.77 -4.78 Nipal3 -3.3 -3.33 -3.28 
C1s -4.96 -4.78 -5.13 Nkain1 1.51 1.79 1.61 
C3 -10.21 -11.03 -9.87 Nkain4 -1.98 -1.94 -1.94 
C330027c
09rik 
3.71 3.87 3.61 Nmb -3.7 -4.22 -3.62 
C4b -6.9 -6.54 -6.92 Nme5 -4.28 -5.11 -4.34 
Cachd1 -2.39 -2.38 -2.31 Nomo1 1.51 1.49 1.52 
Cacnb4 -2.67 -3.56 -2.95 Nos1 -5.59 -6.16 -5.86 
Cad 1.62 1.45 1.54 Npdc1 -1.43 -1.54 -1.31 
Cadm4 -1.63 -1.72 -1.53 Nptx1 4.76 4.83 4.80 
Calcoco1 -1.6 -1.76 -1.55 Nrbp2 -2.48 -2.39 -2.42 
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Calm2 2.24 2.56 2.10 Nrgn 6.02 6.43 6.48 
Calml3 -5.61 -5.75 -5.75 Nrm 3.43 3.52 3.54 
Camk1g 6.24 6.08 6.00 Nsl1 4.08 4.23 3.54 
Camk2b 2.21 3.11 2.24 Ntn1 1.65 1.86 1.71 
Camkk2 1.92 1.80 1.83 Ntn4 1.58 2.20 1.70 
Capg -4.17 -4.00 -4.36 Ntrk2 -2.52 -1.52 -2.47 
Capn1 -5 -4.31 -4.89 Nuak1 -3.03 -3.19 -3.28 
Capn2 -1.61 -1.60 -1.60 Nudt4 -1.61 -1.55 -1.59 
Capns1 -2.21 -2.49 -2.06 Nuf2 5.6 2.36 3.41 
Car3 4.38 4.14 3.93 Nup107 1.87 1.95 1.86 
Car5b -4.88 -4.45 -4.79 Nup188 1.36 1.42 1.41 
Car6 5.4 5.79 5.46 Nup205 1.72 1.92 1.78 
Carns1 -3.36 -2.86 -3.34 Nup210 4.31 4.46 4.26 
Casc5 6.47 7.11 6.00 Nup85 1.73 1.77 1.75 
Casq2 -5.69 -6.32 -5.80 Nusap1 3.7 3.67 3.61 
Cat -1.79 -1.74 -1.77 Nxn -2.27 -2.55 -2.49 
Ccdc103 -3.77 -3.58 -3.82 Nxph3 -3.69 -4.00 -3.53 
Ccdc13 -5.34 -6.09 -5.80 Oat -2.71 -1.93 -2.73 
Ccdc135 -9.85 -10.09 -10.51 Olfm2 2.42 2.60 2.57 
Ccdc148 -5.1 -4.28 -4.93 Olig1 2.31 2.24 2.41 
Ccdc153 -6.34 -8.26 -6.26 Olig2 2.72 2.63 2.82 
Ccdc74a -3.31 -3.33 -2.89 Ophn1 -1.9 -2.12 -1.92 
Ccdc96 -2.67 -2.62 -2.71 Orc1 3.59 4.31 3.63 
Ccna2 4.91 6.75 5.66 Ormdl3 -1.37 -1.70 -1.36 
Ccnb1 7.39 6.92 7.28 Osbpl5 -1.86 -2.07 -2.04 
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Ccnb2 6.6 6.61 6.70 Osgin2 -2.04 -1.95 -2.06 
Ccnd1 4.94 5.09 4.87 Osmr -5.58 -5.01 -5.46 
Ccnd2 3.93 4.25 4.12 Otoa 4.06 4.56 4.17 
Ccne1 3.2 3.29 3.20 P2rx6 -3.46 -4.57 -3.34 
Ccnf 4.72 4.72 4.73 P4ha3 -4.62 -4.49 -4.80 
Cd109 -2.7 -2.65 -2.87 Pacrg -2.87 -3.56 -2.86 
Cd248 3.44 3.74 3.89 Pacs2 -1.55 -1.62 -1.60 
Cd276 1.78 1.86 1.82 Padi2 -6.04 -6.09 -6.09 
Cd38 -4.95 -4.77 -4.30 Palld -1.94 -2.82 -2.05 
Cd44 -1.6 -1.51 -1.74 Palm -1.83 -3.21 -1.72 
Cd93 5.61 5.63 5.37 Paqr4 -2.45 -2.23 -2.39 
Cdc20 6.12 6.08 6.14 Paqr8 -1.67 -1.70 -1.73 
Cdc25b 2.7 2.95 2.76 Pard3b -2.03 -2.12 -2.10 
Cdc25c 6.89 6.36 6.23 Pard6b -3.44 -3.31 -3.33 
Cdc42ep4 -3.37 -3.40 -3.27 Parp3 -3.77 -3.66 -3.56 
Cdc45 4.31 3.29 4.26 Parp4 -1.96 -1.85 -1.96 
Cdc6 4.94 4.91 4.98 Pask 2.74 2.92 2.74 
Cdc7 3.54 3.83 3.65 Pbk 6.92 6.92 6.64 
Cdca2 6.43 7.16 6.51 Pcna 2.28 2.13 2.13 
Cdca3 6.22 6.18 6.17 Pcp4l1 -2.89 -2.81 -2.94 
Cdca5 4.58 4.66 4.66 Pcx -2.09 -2.18 -2.03 
Cdca7 3.99 3.83 4.01 Pdia4 -1.37 -1.32 -1.39 
Cdca8 5.78 5.72 5.85 Pdia5 2.57 2.90 2.89 
Cdh13 2.7 2.73 2.72 Pdk2 -2.07 -2.08 -2.03 
Cdh4 1.74 1.84 1.84 Peg10 1.75 1.88 1.72 
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Cdhr1 5.44 5.12 5.19 Peg12 3.18 3.15 3.25 
Cdk1 5.23 6.64 5.32 Peli2 -2.1 -2.26 -2.31 
Cdkn3 5.47 6.06 5.66 Per1 1.7 3.41 1.69 
Cdon 2.86 2.96 2.83 Pfkfb3 -2.98 3.03 -2.78 
Cdr2l 2.18 2.31 2.39 Pgap1 2.32 2.69 2.31 
Cdt1 4.31 4.28 4.43 Phkg1 -5.14 -5.36 -5.07 
Celsr2 -2.01 -1.87 -1.70 Phyhd1 -3.73 -3.53 -3.78 
Cenpa 5.89 5.79 5.67 Pi15 -6.88 -6.75 -6.76 
Cenpe 5.76 6.12 5.95 Pif1 7.55 7.53 7.55 
Cenpf 7.67 7.75 6.61 Pik3ip1 -2.26 -2.19 -2.15 
Cenph 4.26 4.45 4.37 Pink1 -2.7 -2.68 -2.57 
Cenpi 3.68 4.49 3.69 Pkd1 1.78 1.94 1.94 
Cenpm 6.03 5.70 5.83 Pkp4 -1.84 -2.06 -1.86 
Cenpn 4.36 4.50 4.40 Pla2g1
6 
-1.87 -1.99 -2.01 
Cenpq 3.15 3.16 2.99 Pla2g3 2.8 3.72 3.74 
Cenpw 3.43 3.57 3.52 Plat -1.51 -1.58 -1.58 
Cep55 5.88 4.30 5.41 Plbd2 -1.38 -1.38 -1.34 
Cetn4 -4.18 -4.21 -4.05 Plce1 -4.19 -3.87 -4.24 
Cftr 5.44 5.45 5.35 Pld1 1.68 2.47 1.69 
Chaf1a 2.58 2.55 2.61 Plec -3.78 -4.08 -3.87 
Chaf1b 3.98 3.88 3.89 Plekha
6 
-5.53 -5.52 -5.23 
Chek1 3.98 3.31 3.98 Plekhb
1 
-2.72 -2.67 -2.67 
Chgb -2.87 -2.86 -2.88 Plk1 6.93 6.75 6.99 
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Chi3l1 -5.14 -5.62 -5.26 Plk2 2.09 2.11 2.09 
Chn2 2.18 2.18 1.75 Plk4 4.48 5.51 4.06 
Chrm3 3.85 4.64 3.86 Plp1 -3.06 -3.45 -3.09 
Chst7 4.06 2.94 4.18 Plscr2 -8.18 -7.69 -8.42 
Chst8 -5.06 -5.21 -4.79 Pltp -4.54 -4.82 -4.43 
Chtf18 3.77 3.76 3.89 Plvap 3.64 3.45 3.78 
Ckap2 2.06 2.26 1.94 Plxdc1 -7.18 -7.13 -7.32 
Ckap2l 5.45 4.33 5.41 Plxnb1 -1.97 -1.94 -1.94 
Cks1b 3.14 3.02 3.15 Pmf1 3.02 2.95 3.12 
Cks2 4.04 5.23 4.21 Pnpla7 -1.95 -1.99 -2.01 
Cldn9 -5.68 -5.55 -6.66 Pola1 1.94 2.06 1.88 
Clip4 -2.79 -3.00 -2.82 Pold1 3.46 3.41 3.58 
Clspn 4.63 4.92 4.98 Pole 4.01 4.12 4.08 
Clu -5.62 -6.69 -5.62 Polq 4.19 4.62 4.04 
Cml1 -2.17 -2.62 -2.60 Pom12
1 
1.38 1.46 1.46 
Cmtm5 -2.61 -2.55 -2.49 Porcn -2.36 -3.26 -2.26 
Cmya5 -2.72 -2.73 -2.95 Pou3f1 4.95 4.86 5.13 
Cnn3 -1.5 -1.43 -1.47 Ppp1r3
c 
-2.28 -2.30 -2.37 
Cnp -2.13 -2.13 -2.06 Ppp2r2
b 
-2.53 -2.59 -2.52 
Cobll1 -1.88 -2.52 -1.86 Ppp2r5
a 
-1.81 -1.87 -1.65 
Col22a1 -3.79 -4.01 -3.57 Prc1 5.41 5.40 5.42 
Col23a1 -4.19 -9.47 -3.95 Prdx6 -3.77 -3.20 -3.79 
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Col4a5 -4.28 -4.30 -4.31 Prelp -4.39 -4.31 -4.43 
Col6a1 -2.58 -2.63 -2.57 Prim1 2.87 2.91 2.81 
Col8a2 -4.23 -3.81 -4.20 Prkca -2.07 -1.92 -2.05 
Cotl1 -2.28 -2.26 -2.14 Prkcb 3.76 4.18 3.96 
Cpeb2 -2.02 -2.11 -2.08 Prmt1 1.57 1.59 1.57 
Cpne7 Inf 6.18 6.88 Pros1 -1.59 -1.51 -1.63 
Creb5 3.44 3.48 3.49 Prr11 4.58 4.84 4.33 
Crip2 -1.53 -1.52 -1.40 Prr18 2.56 2.41 2.60 
Crtap 2.02 2.04 2.07 Prune2 -4.66 -5.12 -4.92 
Cryab -3.44 -2.43 -3.40 Psen2 -2.25 -2.19 -2.27 
Crygs -5.12 -4.43 -4.58 Pstpip2 4.35 4.70 4.51 
Csf1 -2.98 -2.87 -2.91 Pth1r -4.24 -5.55 -3.98 
Cspg4 2.41 2.49 2.58 Ptn 1.73 1.74 1.78 
Cspg5 2.57 1.40 1.50 Ptplb -2.96 -3.36 -2.93 
Cst3 -1.98 -1.75 -1.77 Ptprf -1.41 -1.46 -1.34 
Ctnnal1 -2.6 -2.56 -2.61 Ptprj 2.62 2.49 2.40 
Ctps 1.88 1.81 1.63 Pvalb -7.56 -8.58 -7.91 
Ctsf -2.2 -2.19 -2.14 Pygb -3.48 -3.52 -3.44 
Ctsl -2.23 -2.14 -2.24 Rab26 6.88 6.25 6.97 
Cxcr4 -5.72 -5.36 -5.76 Racgap
1 
4.64 4.38 4.68 
Cyp4v3 -3.56 -3.84 -3.71 Rad51 3.34 3.42 3.29 
D10jhu81e -1.6 -1.56 -1.57 Rad51a
p1 
5.11 4.54 5.06 
Daam2 -6.52 -6.50 -6.56 Rad51c 3.28 3.39 3.10 
Dapk1 -2.5 -2.43 -2.33 Ran 1.41 1.66 1.43 
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Dazap1 1.58 1.74 1.74 Rap1ga
p 
3.05 3.13 3.02 
Dbf4 3.58 3.87 3.55 Rasa3 1.82 1.98 1.88 
Dbndd2 -2.98 -2.19 -2.79 Rasal1 6.16 6.71 5.84 
Dcdc2a -5.27 -4.57 -5.06 Rassf3 3.08 3.14 3.10 
Ddo -6.65 -6.75 -6.87 Rb1 -1.93 -1.95 -2.10 
Ddr1 -1.61 -3.51 -1.57 Rbl1 3.29 3.64 3.33 
Ddx11 3.34 3.29 3.28 Rcc1 2.05 2.98 2.13 
Depdc1a 6.72 7.69 7.05 Rcor2 2.22 2.15 2.35 
Depdc1b 5.97 6.15 6.00 Rdh5 -4.82 -3.64 -4.71 
Dgkk 4.52 4.99 4.11 Reep1 -1.79 -1.81 -1.81 
Dgkz 1.7 1.60 1.81 Retsat -2.87 -2.64 -3.06 
Dhcr24 1.63 1.53 1.58 Rev3l 1.81 1.52 1.33 
Dhfr 2.49 2.57 2.41 Rfc3 2.17 2.28 2.23 
Dhrs1 -3.73 -3.72 -3.64 Rfx2 -2.77 -2.81 -2.83 
Dhx32 -2.22 -2.31 -2.22 Rgma -1.41 -1.78 -1.58 
Diap3 4.59 4.44 3.35 Rgs4 -5.87 -5.54 -6.04 
Dirc2 -1.77 -1.77 -1.74 Rgs5 -6.28 -6.65 -7.52 
Dixdc1 -2.46 -3.16 -2.36 Rhbdf1 1.88 2.03 2.01 
Dlgap3 2.05 1.96 2.20 Rhou -2.65 -2.60 -2.60 
Dlgap5 5.6 7.17 5.33 Rhpn2 -3.66 -3.75 -3.71 
Dmp1 3.49 4.07 3.41 Rims4 2.82 4.48 3.11 
Dna2 3.34 3.35 3.34 Rin2 -1.58 -1.64 -1.62 
Dnajb2 -2.04 -2.30 -2.07 Ripply1 -8.44 -8.20 -8.28 
Dnajb4 -1.61 -1.87 -1.60 Rnase1 -8.99 -8.61 -9.03 
Dnajb9 -2.6 -2.50 -2.58 Rnf13 -1.97 -1.89 -2.04 
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Dock10 2.15 2.55 2.37 Rnf182 -3.9 -3.82 -4.01 
Drp2 -4.18 -5.22 -3.49 Rnf19b -2.37 -2.64 -2.41 
Dscc1 6.94 5.62 5.31 Rorc -3.14 -3.46 -3.17 
Dtl 4.76 4.08 4.77 Rpa2 1.84 1.85 1.84 
Dusp18 -2.31 -2.07 -2.26 Rpe65 -7.99 -7.75 -7.52 
Dusp6 6.29 6.23 6.22 Rpl13a 1.34 1.80 1.53 
Dut 2.87 4.09 2.93 Rplp1 1.38 1.53 1.32 
Dync2li1 -2.18 -2.06 -2.13 Rps20 1.54 1.52 1.56 
E2f1 3.92 4.76 3.96 Rps5 1.38 1.57 1.58 
E2f2 5.1 4.88 4.97 Rrm1 1.67 1.82 1.67 
E2f7 5.46 6.20 5.15 Rrm2 4.66 4.78 4.67 
E2f8 4.66 4.18 4.70 Rsph9 -3.27 -3.14 -3.18 
Ech1 -2.13 -2.20 -2.10 Rtkn2 3.99 6.69 4.10 
Ecm2 -3.07 -3.50 -3.81 S100a3 -5.87 -5.65 -6.29 
Ect2 5.12 5.93 4.90 S100a4 -6.64 -7.17 -6.69 
Ednra -2 -1.91 -2.02 S1pr1 -3.23 -3.28 -3.22 
Ednrb -1.85 -2.05 -1.89 Sall3 2.45 2.30 2.51 
Eef1b2 1.4 1.50 1.35 Samd9l -3.36 -3.45 -3.31 
Efhd1 -3.22 -3.31 -3.20 Sbno2 -1.79 -4.02 -2.41 
Efhd2 -2.66 -2.66 -2.59 Scara5 -4.15 -3.80 -4.02 
Efs 1.44 1.47 1.61 Scarb1 2.49 2.31 2.33 
Egr1 3.06 3.00 3.06 Scg3 -2.52 -2.70 -2.58 
Elfn2 3.45 3.15 3.50 Scml2 3.09 3.26 3.13 
Eln 4.51 3.23 3.35 Scp2 -1.37 -1.53 -1.44 
Elovl6 1.98 4.98 2.05 Sdc2 -1.75 -1.70 -1.85 
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Enho -2.28 -2.45 -2.13 Sdc3 1.59 1.63 1.71 
Enkur -6.39 -6.27 -6.38 Sdc4 -2.71 -2.70 -2.70 
Enpp3 5.34 6.55 5.52 Sema5
b 
2.62 2.70 2.80 
Entpd2 -5.66 -5.69 -5.69 Sema6
a 
1.51 2.34 1.63 
Ephb1 -1.57 -1.60 -1.64 Sema6
d 
-1.4 -3.06 -1.44 
Ephx4 -3.2 -3.19 -3.22 Sepp1 -1.89 -1.85 -1.96 
Epn2 1.99 2.21 2.02 Sept6 3.08 6.29 2.96 
Eps15 -1.42 -1.68 -1.58 Sept9 2.32 3.02 2.35 
Erbb2ip -1.45 -1.36 -1.49 Serpina
3n 
-6.34 -6.35 -6.38 
Ercc6l 4.08 4.26 4.05 Serpinb
1a 
-3.87 -4.11 -3.96 
Esco2 5.6 5.84 5.71 Serpinb
1b 
-5.44 -5.47 -5.57 
Espl1 5.48 6.58 6.09 Serpinb
9 
-3.37 -3.18 -3.36 
Esrrb 3.78 4.23 3.87 Serping
1 
-5.23 -5.34 -5.52 
Etv4 3.65 3.37 3.67 Sez6l 1.88 2.33 1.90 
Etv5 4.36 4.36 4.27 Sfxn5 -2.21 -2.20 -2.24 
Exo1 3.93 4.82 4.74 Sgol1 6 5.95 5.93 
Ezh2 2.3 2.60 2.32 Sgol2 4.23 5.15 4.35 
Ezr -3.49 -3.54 -3.54 Shc3 2.65 3.42 2.73 
F3 -2.98 -2.99 -2.98 Shcbp1 5.72 5.86 5.61 
Fads2 -1.82 -1.63 -1.74 Shmt1 3.11 1.90 3.22 
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Fam102a -1.89 -1.76 -1.83 Sidt2 -1.57 -1.54 -1.56 
Fam111a 3.96 3.84 3.74 Sirt2 -1.76 -1.78 -1.73 
Fam129b -3.12 -3.21 -3.02 Ska1 6.84 7.97 6.89 
Fam134b -5.33 -5.09 -5.31 Skp2 2.87 2.96 2.77 
Fam171a1 1.44 3.34 1.48 Slc14a
1 
-9.09 -7.87 -9.24 
Fam179a -3.71 -4.40 -4.15 Slc16a
1 
-3.05 -2.86 -3.07 
Fam189a2 -3.5 -3.53 -3.46 Slc1a5 2.55 2.50 2.60 
Fam20a -2.65 -2.96 -2.84 Slc1a6 3.41 3.47 3.52 
Fam53b -2.12 -1.81 -2.10 Slc22a
23 
-1.57 -1.64 -1.53 
Fam63b -1.45 -1.56 -1.59 Slc22a
5 
-2.53 -2.51 -2.52 
Fam64a 7.53 7.31 7.57 Slc25a
10 
-1.6 -2.07 -1.52 
Fam84b -3.25 -3.37 -3.29 Slc25a
25 
2.65 3.45 2.66 
Fancb 3.6 4.58 4.40 Slc25a
33 
-2.72 -2.67 -2.63 
Fancd2 4.63 5.57 5.32 Slc38a
1 
-3.16 -2.85 -3.21 
Fas -4.65 -4.51 -4.56 Slc39a
1 
-1.44 -1.53 -1.54 
Fbln1 2.87 2.87 3.00 Slc39a
12 
-4.4 -4.32 -4.40 
Fbln2 9.26 9.60 9.62 Slc39a
14 
-2.09 -2.23 -2.11 
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Fbn2 3.91 3.50 3.56 Slc39a
4 
-4.5 -4.43 -4.09 
Fbxo32 -2.67 -2.63 -2.71 Slc41a
1 
-1.86 -1.89 -1.86 
Fbxo5 3.79 3.64 3.72 Slc41a
3 
-2.34 -2.31 -2.35 
Fcgr2b -7.09 -7.54 -6.28 Slc43a
2 
-1.71 -2.11 -1.80 
Fcgrt -2.88 -2.90 -2.86 Slc44a
3 
-6.2 -6.27 -6.44 
Fdps 1.96 1.86 2.01 Slc4a2 -1.99 -1.77 -1.70 
Fen1 2.22 2.20 2.30 Slc4a4 -2.03 -2.65 -2.16 
Fez2 -1.57 -1.67 -1.53 Slc4a8 -2.83 -1.53 -1.50 
Fgd3 -2.67 -2.63 -2.68 Slc6a8 -2.37 -2.00 -2.32 
Fgl2 -4.96 -5.11 -4.81 Slc7a1 2.67 2.90 2.80 
Fignl1 4.07 4.31 4.03 Slc7a1
1 
-2.87 -2.54 -3.12 
Fkbp5 2.5 2.47 2.50 Slc9a3r
1 
-1.76 -2.23 -2.15 
Fmn1 -3.09 -3.18 -3.15 Slfn9 3.98 5.19 3.93 
Fmn2 -3.08 -2.97 -3.15 Slit1 4.7 4.64 4.80 
Fmod -8.28 -7.73 -8.35 Smad6 -4.54 -4.03 -4.41 
Fndc1 4.76 4.22 4.44 Smad9 -3.68 -3.37 -3.73 
Folr1 -7.38 -7.60 -7.50 Smc2 2.6 2.44 2.81 
Fos -1.59 -1.75 -1.60 Smc4 2.21 2.10 1.93 
Foxj1 -3.86 -3.99 -3.76 Smpd1 -1.66 -1.69 -1.59 
Foxm1 4.81 4.81 4.83 Smtn 3.28 3.17 3.36 
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Fras1 2.12 2.06 1.94 Snta1 -3.52 -3.18 -3.18 
Fxyd1 -9.97 -9.67 -9.73 Soat1 -2.22 -1.44 -2.12 
Fxyd7 -7.48 -5.44 -7.71 Socs3 -2.72 -3.09 -2.81 
Fyn 1.45 3.12 1.42 Sorbs1 -2.84 -3.40 -2.98 
Fzd3 -1.54 -1.43 -1.64 Sorbs2 -3.25 -3.38 -3.45 
Gabarapl1 -1.75 -1.72 -1.72 Sorl1 -4.02 -3.94 -3.96 
Gadd45a -2.48 -2.44 -2.64 Sox11 2.1 1.99 1.88 
Gadd45b -3.24 -3.33 -3.10 Sox9 -2.39 -2.39 -2.38 
Gadd45g -2.53 -2.74 -2.39 Spag5 2.53 2.56 2.53 
Garnl3 -3.36 -4.92 -3.35 Spag6 -10.21 -7.54 -8.52 
Gas1 1.97 1.96 2.10 Sparc -2.29 -2.20 -2.39 
Gas2l3 5.04 6.05 4.85 Spata1
7 
-5.52 -4.39 -4.29 
Gbp2 -6.65 -6.56 -6.54 Spc24 6.57 6.26 6.06 
Gdf11 -2.46 -2.16 -2.02 Spc25 4.14 4.31 4.21 
Gdpd2 -2.12 -4.13 -2.06 Spop -1.48 -1.38 -1.54 
Gen1 4.02 4.97 3.93 Spp1 3.96 3.99 3.97 
Gins1 3.56 3.78 3.58 Spred1 3.88 1.69 1.38 
Gja1 -4.95 -4.79 -4.94 Spry1 4.19 2.82 4.26 
Glcci1 2.22 2.22 2.10 Spry2 1.8 2.04 2.13 
Glipr2 -3.24 -3.12 -3.21 Spry4 5.68 5.79 5.76 
Glis3 -4.17 -3.51 -4.18 Spsb1 -2.48 -2.51 -2.41 
Glt25d1 1.43 1.45 1.48 Spsb4 3.03 2.75 2.88 
Glud1 -1.73 -1.72 -1.75 Sqstm1 -1.69 -1.67 -1.66 
Gm11992 -4.35 -4.18 -4.23 Srcin1 -4.99 -4.29 -5.04 
Gm973 -3.5 -3.69 -3.60 Srgap3 -1.46 -1.35 -1.39 
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Gmnn 4.45 4.42 4.54 Srm 1.88 1.86 2.02 
Gnb2l1 1.53 1.66 1.56 St8sia1 1.96 2.05 1.90 
Gpam -3.51 -2.99 -3.39 St8sia2 -4.05 -3.89 -4.03 
Gpd2 -1.82 -1.99 -1.95 Stard13 -2 -1.99 -1.98 
Gpr123 -2.39 -2.32 -2.31 Stard8 -4.4 -3.53 -4.21 
Gpr137b-
ps 
-1.81 -1.67 -1.86 Stil 4.53 6.11 4.55 
Gpr137b -2.6 -2.35 -2.54 Stim1 -2.11 -2.03 -2.14 
Gpr17 -4.9 -5.01 -4.86 Stim2 2.26 2.53 2.16 
Gpr179 -4.13 -6.05 -4.52 Stom -3.18 -3.20 -3.18 
Gpr37l1 -3.78 -3.69 -3.64 Sulf1 -4.63 -3.70 -3.54 
Gpr55 -3.19 -3.09 -3.32 Synpo2 -5.5 -5.85 -6.25 
Gprc5b -2.27 -2.34 -2.30 Tab2 -1.92 -1.89 -1.94 
Gpx1 -2.76 -2.83 -2.64 Tacc3 3.84 3.31 3.64 
Gpx4 -1.72 -2.38 -2.48 Tapbp -1.71 -1.81 -1.92 
Gpx8 -2.26 -2.16 -2.27 Tbc1d2 -2.8 -2.81 -2.96 
Gria1 -5.08 -4.96 -4.90 Tbc1d2
b 
-2.41 -2.33 -2.37 
Grm5 3.61 3.41 3.34 Tbcel -2.82 -3.52 -2.83 
Gsg2 4.97 7.51 4.92 Tcp11l2 -3.61 -3.45 -3.51 
Gstm6 4.16 3.88 4.03 Tecta -4.72 -4.46 -4.50 
Gstm7 2.76 2.88 2.74 Tex264 -2.1 -2.93 -2.00 
Gtse1 1.92 2.44 1.96 Tfdp1 1.33 3.28 1.39 
H2afx 2.84 2.70 2.93 Tgfb2 -2.95 -3.06 -3.06 
H2afz 2.55 2.12 2.43 Tifa -3.69 -3.95 -3.72 
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Hacl1 -1.99 -2.04 -2.00 Timeles
s 
6.94 4.11 3.81 
Hc -5.78 -5.72 -5.81 Timp2 -2.72 -2.61 -2.68 
Hcfc1r1 -2.59 -2.57 -2.65 Tipin 2.08 2.08 2.00 
Hectd2 2.06 2.04 2.18 Tjp2 -1.69 -1.86 -1.74 
Heg1 -2.12 -1.96 -2.09 Tk1 7.8 7.68 8.14 
Hells 4.64 4.63 4.15 Tle2 3.46 3.31 3.17 
Hey1 -2.1 -2.01 -2.04 Tle6 4.72 4.96 4.63 
Hhatl -6.79 -6.29 -6.49 Tlr3 -2.36 -2.63 -2.43 
Hip1 3.5 3.37 3.48 Tm4sf1 -4.47 -4.27 -4.50 
Hirip3 2.24 2.03 2.18 Tmem1
08 
-3.19 -9.98 -3.02 
Hivep2 -1.76 -1.74 -1.63 Tmem1
32b 
-2.84 -2.71 -2.87 
Hmcn1 2.06 2.30 2.06 Tmem1
58 
3.2 3.23 3.44 
Hmga2 5.1 5.67 4.76 Tmem1
73 
2.6 3.42 2.56 
Hmgb2 5.09 4.28 4.38 Tmem4
3 
-1.57 -1.60 -1.59 
Hmgcr 1.48 1.61 1.53 Tmem4
7 
-4.39 -4.39 -4.65 
Hmgn5 2.74 2.67 2.38 Tmpo 1.53 2.84 2.39 
Hmmr 6.62 7.59 5.28 Tnc 6 7.95 5.92 
Hnrnpab 1.59 1.59 1.62 Tnfaip6 2.66 2.68 2.68 
Hopx -5.45 -5.42 -5.33 Tom1l1 -1.92 -2.28 -2.32 
Hprt 2.36 3.67 2.23 Tom1l2 -1.59 -1.49 -1.43 
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Hr -4.73 -4.17 -4.69 Tonsl 3.22 2.48 3.34 
Hrsp12 -3.02 -2.80 -3.00 Top2a 6.24 5.77 6.17 
Hs3st2 Inf 6.61 6.71 Topbp1 1.77 1.98 1.87 
Hs6st2 3.61 4.40 3.53 Tprgl -1.42 -1.39 -1.30 
Hsd17b11 -1.68 -1.72 -1.72 Tpx2 5.38 5.36 5.29 
Hsdl2 -2.92 -2.81 -2.89 Traf4 1.61 1.68 1.69 
Hspa1a -2.93 -3.02 -2.87 Traip 3.39 3.03 2.96 
Hspa2 -2.36 -2.41 -2.35 Trappc
10 
-2.83 -2.80 -2.75 
Hspb6 -3.42 -3.54 -3.43 Trib2 2.9 2.90 2.88 
Hspb8 -7.69 -7.81 -7.51 Trim59 2.72 4.40 2.48 
Htr5b 3.73 3.95 3.79 Trip13 3.71 5.21 3.76 
Hydin 4.36 5.82 4.51 Troap 6.96 6.96 6.99 
Iars 1.42 1.60 1.46 Trp53i1
1 
4.22 4.14 4.26 
Id1 -3.54 -3.70 -3.46 Tsc22d
4 
-1.89 -2.90 -1.78 
Id2 -2.44 -2.49 -2.57 Tspan1
5 
-2.34 -2.31 -2.31 
Id4 -5.81 -6.07 -5.83 Tspan1
7 
-3.65 -3.56 -3.54 
Idi1 1.73 1.54 1.41 Tspan5 2.17 2.27 2.24 
Ifit3 -5.3 -5.53 -5.22 Tspan9 -2.15 -2.39 -2.17 
Igfbp2 5.47 5.31 5.63 Tst -2.6 -2.81 -2.57 
Igfbp3 4.92 5.15 5.09 Ttc12 -4.29 -3.74 -4.12 
Igfbp5 -3.72 -3.44 -3.46 Ttc25 -2.82 -2.91 -2.90 
Igfbpl1 -5.48 -5.32 -5.27 Ttc28 -1.42 -1.45 -1.40 
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Igsf11 -5.1 -5.00 -5.10 Ttc30b -2.62 -2.51 -2.61 
Il1r1 -4.25 -4.21 -4.35 Ttk 5.77 5.97 5.80 
Il6ra -2.97 -2.89 -2.96 Ttyh1 -2.13 -2.08 -1.92 
Il6st -4.12 -3.99 -4.12 Ttyh2 -2.35 -2.17 -2.14 
Impdh1 2.09 2.97 2.16 Ttyh3 1.71 2.19 1.80 
Incenp 4.01 3.78 4.04 Tub 2.5 3.25 2.39 
Inf2 -3.61 -2.84 -2.65 Tubb5 1.89 2.02 1.93 
Insig1 1.75 1.66 1.61 Txlnb -2.8 -2.64 -2.95 
Insm1 2.98 2.95 3.13 Txn1 2.54 2.64 2.68 
Ipo5 1.59 1.70 1.56 Ubash3
b 
2.37 2.56 2.36 
Iqcg -4.33 -2.20 -2.15 Ube2c 7.07 6.90 6.46 
Iqgap3 6.64 5.66 5.54 Ube2t 4.55 4.11 4.08 
Iqub -5.17 -5.03 -4.96 Ucma -7.45 -6.66 -7.26 
Irgm2 -4.3 -3.99 -4.06 Ugp2 -1.91 -2.31 -1.99 
Itfg3 -2.58 -2.87 -2.51 Ugt1a6
a 
-4.04 -3.91 -3.98 
Itga3 -3.34 -3.41 -3.27 Uhrf1 5.5 6.92 5.56 
Itga4 5.38 5.56 5.15 Ulk2 -1.6 -1.54 -1.64 
Itga5 2.03 2.00 2.08 Ung 3.07 3.91 3.09 
Itga8 6.1 3.54 3.51 Usp35 -3.26 -3.18 -3.20 
Itm2b -2.34 -1.51 -2.44 Usp53 -5.08 -4.89 -4.69 
Itm2c -2.72 -2.72 -2.66 Vars 1.89 1.85 1.96 
Itpkb -2.53 -2.83 -2.44 Vash1 2.16 2.26 2.31 
Jak1 -1.81 -1.56 -1.68 Vav3 2.28 2.22 2.26 
Jakmip1 -7.22 -7.02 -8.11 Vdr -7.14 -7.34 -6.78 
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Kat2b -2.01 -2.11 -1.87 Vpreb3 -7.49 -7.98 -6.68 
Kbtbd11 1.36 1.64 1.36 Vrk1 2.92 3.43 2.75 
Kcna6 -2.56 -2.60 -2.46 Vtn -6.16 -5.97 -5.85 
Kcnab2 1.73 2.43 1.77 Vwa3a -5.45 -5.13 -5.12 
Kcnc1 1.96 1.95 2.04 Vwa5a -2.95 -2.92 -3.14 
Kcnc4 3.31 3.34 3.38 Vwc2 2.95 3.28 3.05 
Kcnj9 -4.21 -4.20 -4.11 Wdhd1 3.3 2.83 3.25 
Kcnn2 -3 -2.92 -3.06 Wdr52 -6.96 -4.56 -6.02 
Khdrbs3 1.71 1.91 1.64 Wdr62 1.97 3.13 2.03 
Kif11 4.94 4.98 4.83 Wee1 2.25 2.37 2.35 
Kif14 7.14 7.67 6.41 Wipi1 -2.4 -2.14 -2.31 
Kif15 5.52 5.81 5.26 Wnt11 -5.94 -5.58 -5.78 
Kif18a 2.98 2.97 2.77 Wnt9a -3.63 -3.64 -3.60 
Kif18b 4.24 4.40 4.46 Wwc1 -1.73 -1.55 -1.47 
Kif1c -1.35 -1.45 -1.29 Xdh -4.74 -4.85 -4.66 
Kif20b 5.04 5.98 4.41 Xylt1 2.28 2.45 2.30 
Kif21a -1.78 -2.26 -1.82 Zbtb20 -2.37 -5.18 -2.58 
Kif22 4.54 4.79 4.70 Zbtb7c 2.1 2.11 2.18 
Kif23 7.27 6.83 6.71 Zdhhc2
3 
-4.3 -4.18 -4.26 
Kif2c 6.74 6.99 6.65 Zeb1 1.64 1.55 1.58 
Kif4 5.04 5.27 5.12 Zfp651 -2.09 -2.05 -1.91 
Kif6 -5.56 -5.72 -5.36 Zfp703 -1.88 -1.96 -1.84 
Kif9 -4.39 -4.24 -4.41 Zhx1 -1.75 -1.78 -1.81 
Kifc1 3.79 3.57 3.75 Zhx2 -1.76 -1.85 -1.74 
Kifc5b 3.82 3.51 3.77 Zwilch 3.05 3.27 3.07 
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Supplementary Table 5. Transcripts differentially expressed in NSCs and Diff-NSCs identified by 
all three methods. 
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